

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptabf1626

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 JUL 20 Powerful new interactive analysis and visualization software,
STN AnaVist, now available
NEWS 4 AUG 11 Derwent World Patents Index(R) web-based training during
August
NEWS 5 AUG 11 STN AnaVist workshops to be held in North America
NEWS 6 AUG 30 CA/CAPLUS - Increased access to 19th century research documents
NEWS 7 AUG 30 CASREACT - Enhanced with displayable reaction conditions
NEWS 8 SEP 09 ACD predicted properties enhanced in REGISTRY/ZREGISTRY

NEWS EXPRESS JUNE 13 CURRENT WINDOWS VERSION IS V8.0, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 14:57:38 ON 12 SEP 2005

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 14:57:49 ON 12 SEP 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 11 SEP 2005 HIGHEST RN 862883-42-9
DICTIONARY FILE UPDATES: 11 SEP 2005 HIGHEST RN 862883-42-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when
conducting SmartSELECT searches.



```
*****
*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,   *
* effective March 20, 2005. A new display format, IDERL, is now    *
* available and contains the CA role and document type information. *
*
*****
```

Structure search iteration limits have been increased. See HELP SLIMITS
for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10626406\c.str



chain nodes :

6 8 9 10 11

ring nodes :

1 2 3 4 5

chain bonds :

3-8 4-9 5-6 9-10 9-11

ring bonds :

1-2 1-5 2-3 3-4 4-5

exact/norm bonds :

1-2 1-5 2-3 3-4 3-8 4-5 5-6 9-10 9-11

exact bonds :

4-9

G1:O,S

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 8:CLASS 9:CLASS 10:CLASS 11:CLASS

L1 STRUCTURE UPLOADED

=> s l1

SAMPLE SEARCH INITIATED 14:58:10 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 14 TO ITERATE

100.0% PROCESSED 14 ITERATIONS 14 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
 BATCH **COMPLETE**
PROJECTED ITERATIONS: 56 TO 504
PROJECTED ANSWERS: 56 TO 504

L2 14 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 14:58:16 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 237 TO ITERATE

100.0% PROCESSED 237 ITERATIONS 210 ANSWERS
SEARCH TIME: 00.00.01

L3 210 SEA SSS FUL L1

=> file hcaplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	161.33	161.54

FILE 'HCAPLUS' ENTERED AT 14:58:20 ON 12 SEP 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 12 Sep 2005 VOL 143 ISS 12
FILE LAST UPDATED: 11 Sep 2005 (20050911/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3


L4 19 L3

=> d'ibib hitstr 1-19

L4 ANSWER 1 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2005:729564 HCAPLUS
DOCUMENT NUMBER: 143:186693
TITLE: Compositions and methods of use for tyrosine kinase inhibitors to treat pathogenic infection
INVENTOR(S): Kalman, Daniel; Bornmann, William Gerard; Sherman, Melanie Anne; Reeves, Patrick Michael; Swimm, Alyson Irene
PATENT ASSIGNEE(S): Emory University, USA
SOURCE: PCT Int. Appl., 65 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005072826	A2	20050811	WO 2005-US1710	20050120
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
PRIORITY APPLN. INFO.:				
			US 2004-537960P	P 20040121
			US 2004-553681P	P 20040316
			US 2004-614203P	P 20040929


IT 252003-65-9, CP-547632
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tyrosine kinase inhibitors for treatment of pathogenic infection)
RN 252003-65-9 HCAPLUS
CN 4-Isothiazolecarboxamide, 3-[(4-bromo-2,6-difluorophenyl)methoxy]-5-[[[4-(1-pyrrolidinyl)butyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



L4 ANSWER 2 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2005:303191 HCAPLUS
DOCUMENT NUMBER: 142:341966
TITLE: Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases
INVENTOR(S): Schultz, Clyde L.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 7 pp., Cont.-in-part of U.S. Ser. No. 821,718.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005074497	A1	20050407	US 2004-971997	20041022
PRIORITY APPLN. INFO.:			US 2003-461354P	P 20030409
			US 2004-821718	A2 20040409

IT 252003-65-9, CP-547632
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hydrogels containing drugs for treatment of eye diseases in posterior segment)
RN 252003-65-9 HCAPLUS
CN 4-Isouthiazolecarboxamide, 3-[(4-bromo-2,6-difluorophenyl)methoxy]-5-[[[4-(1-pyrrolidinyl)butyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)




L4 ANSWER 3 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:995713 HCAPLUS
DOCUMENT NUMBER: 141:420610
TITLE: Surface receptor complexes as biomarkers of disease and for determination of treatment with dimer-acting drugs
INVENTOR(S): Chan-Hui, Po-Ying; Dua, Rajiv; Mukherjee, Ali; Pidaparathi, Sailaja; Salimi-Moosavi, Hossein; Shi, Yining; Singh, Sharat
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 67 pp., Cont.-in-part of U.S. Ser. No. 623,057.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 32
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004229293	A1	20041118	US 2004-812619	20040330
US 2003013126	A1	20030116	US 2002-154042	20020521
US 2004126818	A1	20040701	US 2003-623057	20030717
US 2004197835	A1	20041007	US 2004-830543	20040422
WO 2005019470	A2	20050303	WO 2004-US25945	20040810
WO 2005019470	A3	20050809		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
PRIORITY APPLN. INFO.:				
			US 2002-154042	A2 20020521
			US 2002-398724P	P 20020725
			US 2003-459888P	P 20030401
			US 2003-623057	A2 20030717
			US 2003-494482P	P 20030811
			US 2003-508034P	P 20031001
			US 2003-512941P	P 20031020
			US 2003-523258P	P 20031118
			US 2001-292548P	P 20010521
			US 2001-334901P	P 20011024

IT 252003-65-9, CP-547632
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(surface receptor complexes as biomarkers of disease or responsiveness to treatment)
RN 252003-65-9 HCAPLUS
CN 4-Isouthiazolecarboxamide, 3-[(4-bromo-2,6-difluorophenyl)methoxy]-5-[[[4-(1-pyrrolidinyl)butyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




L4 ANSWER 4 OF 19 HCAPIUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:965067 HCAPIUS
DOCUMENT NUMBER: 141:406039
TITLE: Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis
INVENTOR(S): Hilberg, Frank; Solca, Flavio; Stefanic, Martin; Friedrich; Baum, Anke; Munzert, Gerd; Van Meel, Jacobus C. A.
PATENT ASSIGNEE(S): Boehringer Ingelheim International G.m.b.H., Germany; Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G.
SOURCE: PCT Int. Appl., 101 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004096224	A2	20041111	WO 2004-EP4363	20040424
WO 2004096224	A3	20041216		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP 1473043	A1	20041103	EP 2003-9587	20030429
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
PRIORITY APPLN. INFO.:			EP 2003-9587	A 20030429
			EP 2004-508	A 20040113
			EP 2004-1171	A 20040121

IT 252003-65-9, CP-547632
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(drug combinations for diseases involving cell proliferation and migration or apoptosis or angiogenesis including protein tyrosine kinase receptor antagonists and radiotherapy)
RN 252003-65-9 HCAPIUS
CN 4-Isouthiazolecarboxamide, 3-[(4-bromo-2,6-difluorophenyl)methoxy]-5-[[[4-(1-pyrrolidinyl)butyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 19 HCAPIUS COPYRIGHT 2005 ACS on STN (Continued)




L4 ANSWER 5 OF 19 HCAPIUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:905883 HCAPIUS
DOCUMENT NUMBER: 141:361107
TITLE: Methods for the detection of cell surface receptor complexes as cancer biomarkers and therapeutic effectiveness of cleavage thereof
INVENTOR(S): Chan-Hui, Po-Ying; Salimi-Moosavi, Hossein; Shi, Yining; Singh, Sharat; Dua, Rajiv; Mukherjee, Ali; Fiduparthi, Sallaja
PATENT ASSIGNEE(S): Aclara Biosciences, Inc., USA
SOURCE: PCT Int. Appl., 106 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 32
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004092353	A2	20041028	WO 2004-US9717	20040330
WO 2004092353	A3	20050303		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2004126818	A1	20040701	US 2003-623057	20030717
WO 2005019470	A2	20050303	WO 2004-US25945	20040810
WO 2005019470	A3	20050609		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
PRIORITY APPLN. INFO.:			US 2003-459888P	P 20030401
			US 2003-623057	A 20030717
			US 2003-494822P	P 20030811
			US 2003-508034P	P 20031001
			US 2003-512941P	P 20031020
			US 2003-523258P	P 20031118
			US 2002-398724P	P 20020725

IT 252003-65-9, CP547632
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(methods for detection of cell surface receptor complexes as cancer biomarkers and therapeutic effectiveness of cleavage thereof)
RN 252003-65-9 HCAPIUS
CN 4-Isouthiazolecarboxamide, 3-[(4-bromo-2,6-difluorophenyl)methoxy]-5-[[[4-(1-pyrrolidinyl)butyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 19 HCAPIUS COPYRIGHT 2005 ACS on STN (Continued)



L4 ANSWER 6 OF 19 HCAPIUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:609931 HCAPIUS
DOCUMENT NUMBER: 141:140432
TITLE: Preparation of ureidoisothiazolecarboxamides as inhibitors of the transforming growth factor (TGF- β) signaling pathway.
INVENTOR(S): Munchhof, Michael J.
PATENT ASSIGNEE(S): Pfizer Inc, USA
SOURCE: U.S. Pat. Appl. Publ., 15 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004147574	A1	20040729	US 2004-765658	20040126
WO 2004067530	A1	20040812	WO 2004-IB122	20040115

W: AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DM, EC, EC, EE, EE, EG, EG, ES, ES, FI, FI, GB, GB, GE, GE, GH, GH, HR, HR, HU, HU, ID, ID, IL, IL, IS, JP, JP, KE, KE, KG, KG, KP, KP, KR, KR, KZ, KZ, LC, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MG, MN, MW, MX, MX, MZ, MZ, NA, NI

PRIORITY APPL. INFO.:

US 2003-442708P P 20030127

OTHER SOURCE(S):

MARPAT 141:140432

IT 727359-37-7P 727359-38-8P 727359-39-9P
727359-40-2P 727359-41-3P 727359-42-4P
727359-43-5P 727359-44-6P 727359-45-7P
727359-46-8P 727359-47-9P 727359-48-0P
727359-49-1P 727359-50-4P 727359-51-5P
727359-52-6P 727359-53-7P 727359-54-8P
727359-55-9P 727359-56-0P 727359-57-1P
727359-58-2P 727359-59-3P 727359-60-6P
727359-61-7P 727359-62-8P 727359-63-9P
727359-64-0P 727359-65-1P 727359-66-2P
727359-67-3P 727359-68-4P 727359-69-5P
727359-70-8P 727359-71-9P 727359-72-0P
727359-73-1P 727359-74-2P 727359-75-3P
727359-76-4P 727359-77-5P 727359-78-6P
727359-79-7P 727359-80-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(claimed compound; preparation of isothiazolecarboxamides as inhibitors of


the

TGF- β signaling pathway)

RN 727359-37-7 HCAPIUS


CN 4-Isouthiazolecarboxamide, 5-[[[2-(1-cyclohexen-1-yl)ethyl]amino]carbonyl]amino]-3-(3-pyridinylmethoxy)- (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 19 HCAPIUS COPYRIGHT 2005 ACS on STN (Continued)



RN 727359-38-8 HCAPIUS


CN 4-Isouthiazolecarboxamide, 5-[[[2-(2,5-dimethylphenyl)methyl]amino]carbonyl]amino]-3-(3-pyridinylmethoxy)- (9CI) (CA INDEX NAME)



RN 727359-39-9 HCAPIUS


CN 4-Isouthiazolecarboxamide, 5-[[[2-(3,5-dimethoxyphenyl)methyl]amino]carbonyl]amino]-3-(3-pyridinylmethoxy)- (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 19 HCAPIUS COPYRIGHT 2005 ACS on STN (Continued)



RN 727359-40-2 HCAPIUS


CN 4-Isouthiazolecarboxamide, 5-[[[2-(2-ethoxyphenyl)methyl]amino]carbonyl]amino]-3-(3-pyridinylmethoxy)- (9CI) (CA INDEX NAME)



RN 727359-41-3 HCAPIUS


CN 4-Isouthiazolecarboxamide, 5-[[[2-(2-ethoxyphenyl)ethyl]amino]carbonyl]amino]-3-(3-pyridinylmethoxy)- (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 19 HCAPIUS COPYRIGHT 2005 ACS on STN (Continued)



RN 727359-42-4 HCAPIUS


CN 4-Isouthiazolecarboxamide, 5-[[[2-(3,4-dimethoxyphenyl)ethyl]amino]carbonyl]amino]-3-(3-pyridinylmethoxy)- (9CI) (CA INDEX NAME)




RN 727359-43-5 HCAPIUS

CN 4-Isouthiazolecarboxamide, 5-[[[2-(2-phenylethyl)amino]carbonyl]amino]-3-(3-pyridinylmethoxy)- (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 727359-44-6 HCAPLUS
 CN 4-isothiazolecarboxamide, 5-[[[2-(3-ethoxy-4-methoxyphenyl)ethyl]amino]carbonyl]amino]-3-(3-pyridinylmethoxy)- (9CI)
 (CA INDEX NAME)




RN 727359-45-7 HCAPLUS
 CN 4-isothiazolecarboxamide, 5-[[[2-(4-ethoxyphenyl)ethyl]amino]carbonyl]amino]-3-(3-pyridinylmethoxy)- (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 727359-46-8 HCAPLUS
 CN 4-isothiazolecarboxamide, 5-[[[2-(4-chlorophenyl)ethyl]amino]carbonyl]amino]-3-(3-pyridinylmethoxy)- (9CI) (CA INDEX NAME)




RN 727359-47-9 HCAPLUS
 CN 4-isothiazolecarboxamide, 5-[[[2-(3-chlorophenyl)ethyl]amino]carbonyl]amino]-3-(3-pyridinylmethoxy)- (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 727359-48-0 HCAPLUS
 CN 4-isothiazolecarboxamide, 5-[[[2-(3-methoxyphenyl)ethyl]amino]carbonyl]amino]-3-(3-pyridinylmethoxy)- (9CI) (CA INDEX NAME)




RN 727359-49-1 HCAPLUS
 CN 4-isothiazolecarboxamide, 5-[[[2-(4-methoxyphenyl)ethyl]amino]carbonyl]amino]-3-(3-pyridinylmethoxy)- (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 727359-50-4 HCAPLUS
 CN 4-isothiazolecarboxamide, 5-[[[2-(3-bromo-4-methoxyphenyl)ethyl]amino]carbonyl]amino]-3-(3-pyridinylmethoxy)- (9CI) (CA INDEX NAME)




RN 727359-51-5 HCAPLUS
 CN 4-isothiazolecarboxamide, 5-[[[2-(4-bromophenyl)ethyl]amino]carbonyl]amino]-3-(3-pyridinylmethoxy)- (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 727359-52-6 HCAPLUS
 CN 4-Isouthiazolecarboxamide, 5-[[[2-(2-chlorophenyl)ethyl]amino]carbonyl]amino]-3-(3-pyridinylmethoxy)- (9CI) (CA INDEX NAME)




RN 727359-53-7 HCAPLUS
 CN 4-Isouthiazolecarboxamide, 5-[[[2-(2-fluorophenyl)ethyl]amino]carbonyl]amino]-3-(3-pyridinylmethoxy)- (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 727359-54-8 HCAPLUS
 CN 4-Isouthiazolecarboxamide, 5-[[[2-(3-fluorophenyl)ethyl]amino]carbonyl]amino]-3-(3-pyridinylmethoxy)- (9CI) (CA INDEX NAME)




RN 727359-55-9 HCAPLUS
 CN 4-Isouthiazolecarboxamide, 5-[[[2-(4-fluorophenyl)ethyl]amino]carbonyl]amino]-3-(3-pyridinylmethoxy)- (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 727359-56-0 HCAPLUS
 CN 4-Isouthiazolecarboxamide, 5-[[[2-(4-ethoxy-3-methoxyphenyl)ethyl]amino]carbonyl]amino]-3-(3-pyridinylmethoxy)- (9CI) (CA INDEX NAME)




RN 727359-57-1 HCAPLUS
 CN 4-Isouthiazolecarboxamide, 5-[[[2-(2,5-dimethoxyphenyl)ethyl]amino]carbonyl]amino]-3-(3-pyridinylmethoxy)- (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 727359-58-2 HCAPLUS
 CN 4-Isouthiazolecarboxamide, 5-[[[2-(difluoromethoxy)phenyl]methyl]amino]carbonyl]amino]-3-(3-pyridinylmethoxy)- (9CI) (CA INDEX NAME)




RN 727359-59-3 HCAPLUS
 CN 4-Isouthiazolecarboxamide, 5-[[[2-(2,6-dimethoxyphenyl)methyl]amino]carbonyl]amino]-3-(3-pyridinylmethoxy)- (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 19 HCAPIUS COPYRIGHT 2005 ACS on STN (Continued)




RN 727359-60-6 HCAPIUS
 CN 4-Isythiazolecarboxamide, 5-[[[2-(3-pyridinylmethoxy)-5-methoxyphenyl]methyl]amino]carbonyl]amino]-3-(3-pyridinylmethoxy)- (9CI) (CA INDEX NAME)




RN 727359-61-7 HCAPIUS
 CN 4-Isythiazolecarboxamide, 5-[[[3-(4-morpholinyl)propyl]amino]carbonyl]amino]-3-(3-pyridinylmethoxy)- (9CI) (CA INDEX NAME)


L4 ANSWER 6 OF 19 HCAPIUS COPYRIGHT 2005 ACS on STN (Continued)



RN 727359-64-0 HCAPIUS
 CN 4-Isythiazolecarboxamide, 5-[[[3-(diethylamino)propyl]amino]carbonyl]amino]-3-(3-pyridinylmethoxy)- (9CI) (CA INDEX NAME)




RN 727359-65-1 HCAPIUS
 CN 4-Isythiazolecarboxamide, 5-[[[2-(1-methyl-2-pyrrolidinyl)ethyl]amino]carbonyl]amino]-3-(3-pyridinylmethoxy)- (9CI) (CA INDEX NAME)




RN 727359-66-2 HCAPIUS
 CN 4-Isythiazolecarboxamide, 5-[[[3-(2-methyl-1-piperidinyl)propyl]amino]carbonyl]amino]-3-(3-pyridinylmethoxy)- (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 19 HCAPIUS COPYRIGHT 2005 ACS on STN (Continued)




RN 727359-62-8 HCAPIUS
 CN 4-Isythiazolecarboxamide, 5-[[[2-(4-morpholinyl)ethyl]amino]carbonyl]amino]-3-(3-pyridinylmethoxy)- (9CI) (CA INDEX NAME)




RN 727359-63-9 HCAPIUS
 CN 4-Isythiazolecarboxamide, 5-[[[2-(diethylamino)ethyl]amino]carbonyl]amino]-3-(3-pyridinylmethoxy)- (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 19 HCAPIUS COPYRIGHT 2005 ACS on STN (Continued)




RN 727359-67-3 HCAPIUS
 CN 4-Isythiazolecarboxamide, 5-[[[3-(diethylamino)propyl]amino]carbonyl]amino]-3-(3-pyridinylmethoxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 727359-68-4 HCAPIUS
 CN 4-Isythiazolecarboxamide, 5-[[[3-(diethylamino)propyl]amino]carbonyl]amino]-3-(3-pyridinylmethoxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 727359-69-5 HCAPIUS
 CN 4-Isythiazolecarboxamide, 5-[[[3-(diethylamino)propyl]amino]carbonyl]amino]-3-(3-pyridinylmethoxy)- (9CI) (CA INDEX NAME)


L4 ANSWER 6 OF 19 HCAPIUS COPYRIGHT 2005 ACS on STN (Continued)




RN 727359-70-8 HCAPIUS
 CN 4-Isouthiazolecarboxamide, 5-[[[(2-hydroxybutyl)amino]carbonyl]amino]-3-(3-pyridinylmethoxy)- (9CI) (CA INDEX NAME)



RN 727359-71-9 HCAPIUS
 CN 4-Isouthiazolecarboxamide, 5-[[[(2-oxo-1-pyrrolidinyl)propyl]amino]carbonyl]amino]-3-(3-pyridinylmethoxy)- (9CI) (CA INDEX NAME)




RN 727359-72-0 HCAPIUS
 CN 4-Isouthiazolecarboxamide, 5-[[[(3-(1H-imidazol-1-yl)propyl)amino]carbonyl]amino]-3-(3-pyridinylmethoxy)- (9CI) (CA INDEX NAME)




RN 727359-73-1 HCAPIUS

L4 ANSWER 6 OF 19 HCAPIUS COPYRIGHT 2005 ACS on STN (Continued)




RN 727359-76-4 HCAPIUS
 CN 4-Isouthiazolecarboxamide, 5-[[[(2,6-dimethoxyphenyl)methyl]amino]carbonyl]amino]-3-[1-(3-pyridinyl)ethoxy]- (9CI) (CA INDEX NAME)




RN 727359-77-5 HCAPIUS
 CN 4-Isouthiazolecarboxamide, 5-[[[(cyclopropylmethyl)amino]carbonyl]amino]-3-(3-pyridinylmethoxy)- (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 19 HCAPIUS COPYRIGHT 2005 ACS on STN (Continued)
 CN 4-Isouthiazolecarboxamide, 5-[[[(phenylmethyl)amino]carbonyl]amino]-3-(3-pyridinylmethoxy)- (9CI) (CA INDEX NAME)




RN 727359-74-2 HCAPIUS
 CN 4-Isouthiazolecarboxamide, 5-[[[(2,5-difluorophenyl)methyl]amino]carbonyl]amino]-3-(3-pyridinylmethoxy)- (9CI) (CA INDEX NAME)




RN 727359-75-3 HCAPIUS
 CN 4-Isouthiazolecarboxamide, 3-[1-(3-pyridinyl)ethoxy]-5-[[[(2-pyridinylmethyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)


L4 ANSWER 6 OF 19 HCAPIUS COPYRIGHT 2005 ACS on STN (Continued)



RN 727359-78-6 HCAPIUS
 CN 4-Isouthiazolecarboxamide, 5-[[[(methylamino)carbonyl]amino]-3-(3-pyridinylmethoxy)- (9CI) (CA INDEX NAME)




RN 727359-79-7 HCAPIUS
 CN 4-Isouthiazolecarboxamide, 5-[[[(methylamino)carbonyl]amino]-3-[1-(3-pyridinyl)ethoxy]- (9CI) (CA INDEX NAME)




RN 727359-80-0 HCAPIUS
 CN 4-Isouthiazolecarboxamide, 5-[[[(3,5-dichlorophenyl)methyl]amino]carbonyl]amino]-3-(3-pyridinylmethoxy)- (9CI) (CA INDEX NAME)


L4 ANSWER 6 OF 19 HCAPLUS COPYRIGHT 2005 ACS ON STN (Continued)



IT 252004-30-1
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of isothiazolecarboxamides as inhibitors of the TGF- β signaling pathway)
 RN 252004-30-1 HCAPLUS
 CN Carbamic acid, [4-(aminocarbonyl)-2,3-dihydro-3-oxo-5-isothiazolyl]-, phenyl ester (9CI) (CA INDEX NAME)




L4 ANSWER 7 OF 19 HCAPLUS COPYRIGHT 2005 ACS ON STN (Continued)
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (combination therapy for hyperproliferative diseases by coadministration of isothiazole deriv. and other antitumor agents)
 RN 252003-37-5 HCAPLUS
 CN 4-isothiazolecarboxamide, 3-[(2,5-difluoro-4-methylphenyl)methoxy]-5-[[[4-(dimethylamino)hexyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 252003-44-4 HCAPLUS
 CN 4-isothiazolecarboxamide, 3-[(4-chloro-2,6-difluorophenyl)methoxy]-5-[[[3-hydroxy-5-(1-pyrrolidinyl)pentyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

Cl


RN 252003-53-5 HCAPLUS
 CN 4-isothiazolecarboxamide, 3-[(2-fluoro-4-methylphenyl)methoxy]-5-[[[3-(4-methyl-1-piperazinyl)propyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)

L4 ANSWER 7 OF 19 HCAPLUS COPYRIGHT 2005 ACS ON STN
 ACCESSION NUMBER: 2004:182702 HCAPLUS
 DOCUMENT NUMBER: 140:229421
 TITLE: Combination therapy for hyperproliferative diseases by coadministration of isothiazole derivative and other antitumor agents
 INVENTOR(S): Beebe, Jean Saccuzzo; Ferrante, Karen Jean; Jani, Jitesh Pranal; Schaeffer, Tracey Lee; Healey, Diane Ingeborg; O'Leary, James John
 PATENT ASSIGNEE(S): Pfizer Products Inc., USA
 SOURCE: PCT Int. Appl., 52 pp.
 CODEN: FIXX02
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004017964	A1	20040304	WO 2003-183550	20030807
W:	AL, AG, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SM, TD, TG			
CA 2495962	AA	20040304	CA 2003-2495962	20030807
EP 1545519	A1	20050629	EP 2003-792573	20030807
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
BR 2003013593	A	20050712	BR 2003-13593	20030807
PRIORITY APPLN. INFO.:			US 2002-404461P	P 20020819
			WO 2003-183550	W 20030807

OTHER SOURCE(S): MARPAT 140:229421
 IT 252003-37-5 252003-44-4 252003-53-5
 252003-54-6 252003-55-7 252003-56-8
 252003-57-9 252003-58-0 252003-59-1
 252003-60-4 252003-61-5 252003-62-6
 252003-63-7 252003-64-8 252003-65-9
 3-(4-Bromo-2,6-difluorobenzoyloxy)-5-[3-(4-pyrrolidin-1-ylbutyl)ureido]isothiazole-4-carboxylic acid amide 252003-66-0
 252003-68-2 252003-69-3 252003-70-6
 252003-71-7 252003-72-8 252003-73-9
 252003-74-0 252003-75-1 252003-76-2
 252003-77-3 252003-78-4 252003-80-8
 252003-81-9 252003-82-0 252003-83-1
 252003-84-2 252003-85-3 252003-86-4
 252003-87-5 252003-88-6 252003-89-7
 252003-90-0 252003-91-1 252003-92-2
 252003-94-4 252003-95-5 252003-96-6
 252003-97-7 252003-98-8 252003-99-9
 252004-00-5 252004-01-6 252004-02-7
 252004-03-8 252004-04-9 252004-05-0
 252004-07-2 252004-08-3 252004-09-4
 252004-11-8 252004-12-9 666849-35-0

L4 ANSWER 7 OF 19 HCAPLUS COPYRIGHT 2005 ACS ON STN (Continued)




RN 252003-54-6 HCAPLUS
 CN 4-isothiazolecarboxamide, 3-[(2,6-difluoro-4-methylphenyl)methoxy]-5-[[[4-(1-pyrrolidinyl)butyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 252003-55-7 HCAPLUS
 CN 4-isothiazolecarboxamide, 3-[(2,6-difluoro-4-methylphenyl)methoxy]-5-[[[4-(4-(2-hydroxyethyl)-1-piperazinyl)butyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)

L4 ANSWER 7 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 252003-56-8 HCAPLUS
 CN 4-Isothiazolecarboxamide, 3-((2,6-difluoro-4-methylphenyl)methoxy)-5-([3-hydroxy-5-(1-pyrrolidinyl)pentyl]amino)carbonylamino- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B


Me

RN 252003-57-9 HCAPLUS
 CN 4-Isothiazolecarboxamide, 5-([4-(1-pyrrolidinyl)butyl]amino)carbonylamino-3-((2,3,6-trifluoro-4-methylphenyl)methoxy)- (9CI) (CA INDEX NAME)


L4 ANSWER 7 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 252003-58-0 HCAPLUS
 CN 4-Isothiazolecarboxamide, 5-([2-(1-methyl-2-pyrrolidinyl)ethyl]amino)carbonylamino-3-((2,3,6-trifluoro-4-methylphenyl)methoxy)- (9CI) (CA INDEX NAME)




RN 252003-59-1 HCAPLUS
 CN 4-Isothiazolecarboxamide, 5-([4-(dimethylamino)butyl]amino)carbonylamino-3-((2,3,6-trifluoro-4-methylphenyl)methoxy)- (9CI) (CA INDEX NAME)




RN 252003-60-4 HCAPLUS
 CN 4-Isothiazolecarboxamide, 5-([3-hydroxy-5-(1-methylethyl)amino]pentyl)amino)carbonylamino-3-((2,3,6-trifluoro-4-methylphenyl)methoxy)- (9CI) (CA INDEX NAME)


L4 ANSWER 7 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 252003-61-5 HCAPLUS
 CN 4-Isothiazolecarboxamide, 5-([4-(2-hydroxyethyl)-1-piperazinyl]butyl]amino)carbonylamino-3-((2,3,6-trifluoro-4-methylphenyl)methoxy)- (9CI) (CA INDEX NAME)




RN 252003-62-6 HCAPLUS
 CN 4-Isothiazolecarboxamide, 3-((2,6-difluoro-4-methylphenyl)methoxy)-5-([2-(1-methyl-2-pyrrolidinyl)ethyl]amino)carbonylamino- (9CI) (CA INDEX NAME)




RN 252003-63-7 HCAPLUS
 CN 4-Isothiazolecarboxamide, 3-((4-bromo-2,3,6-trifluorophenyl)methoxy)-5-([4-(1-pyrrolidinyl)butyl]amino)carbonylamino- (9CI) (CA INDEX NAME)


L4 ANSWER 7 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 252003-64-8 HCAPLUS
 CN 4-Isothiazolecarboxamide, 5-([4-(bis(2-hydroxyethyl)amino)butyl]amino)carbonylamino-3-((2,6-difluoro-4-methylphenyl)methoxy)- (9CI) (CA INDEX NAME)



RN 252003-65-9 HCAPLUS
 CN 4-Isothiazolecarboxamide, 3-((4-bromo-2,6-difluorophenyl)methoxy)-5-([4-(1-pyrrolidinyl)butyl]amino)carbonylamino- (9CI) (CA INDEX NAME)




RN 252003-66-0 HCAPLUS
 CN 4-Isothiazolecarboxamide, 3-((4-bromo-2,6-difluorophenyl)methoxy)-5-([4-(1-pyrrolidinyl)butyl]amino)carbonylamino- (9CI) (CA INDEX NAME)

CH 1

CRN 252003-65-9
 CMF C20 H24 Br F2 N5 O3 S


L4 ANSWER 7 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



CM 2


CRN 75-75-2
CMF C H4 O3 S

RN 252003-68-2 HCAPLUS
CN 4-Isothiazolecarboxamide, 3-[(4-chloro-2,6-difluorophenyl)methoxy]-5-[[[4-(ethyl(2-hydroxyethyl)amino)butyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 252003-69-3 HCAPLUS
CN 4-Isothiazolecarboxamide, 3-[(2,5-difluoro-4-methylphenyl)methoxy]-5-[[[4-(2-hydroxyethyl)-1-piperazinyl]butyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)

L4 ANSWER 7 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




● HCl

RN 252003-72-8 HCAPLUS
CN 4-Isothiazolecarboxamide, 3-[(4-chloro-2,6-difluorophenyl)methoxy]-5-[[[4-(1-pyrrolidinyl)butyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 252003-73-9 HCAPLUS
CN 4-Isothiazolecarboxamide, 3-[(4-chloro-2,6-difluorophenyl)methoxy]-5-[[[4-(4-methyl-1-piperazinyl)propyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 252003-74-0 HCAPLUS

L4 ANSWER 7 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 252003-70-6 HCAPLUS
CN 4-Isothiazolecarboxamide, 3-[(2-fluoro-4-methylphenyl)methoxy]-5-[[[5-[(1-methylethyl)amino]pentyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 252003-71-7 HCAPLUS
CN 4-Isothiazolecarboxamide, 3-[(4-bromo-2,6-difluorophenyl)methoxy]-5-[[[4-(1-pyrrolidinyl)butyl]amino]carbonyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 7 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 252003-71-7 HCAPLUS
CN 4-Isothiazolecarboxamide, 3-[(4-bromo-2,6-difluorophenyl)methoxy]-5-[[[4-(1-pyrrolidinyl)butyl]amino]carbonyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



RN 252003-75-1 HCAPLUS
CN 4-Isothiazolecarboxamide, 3-[(2,5-difluoro-4-methylphenyl)methoxy]-5-[[[4-(3,4-dihydroxy-1-pyrrolidinyl)butyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 252003-76-2 HCAPLUS
CN 4-Isothiazolecarboxamide, 3-[(4-chloro-2,6-difluorophenyl)methoxy]-5-[[[4-(3,4-dihydroxy-1-pyrrolidinyl)butyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 252003-77-3 HCAPLUS
CN 4-Isothiazolecarboxamide, 3-[(2,5-difluoro-4-methylphenyl)methoxy]-5-[[[4-(2-hydroxyethyl)-1-piperazinyl]butyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)


L4 ANSWER 7 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 252003-78-4 HCAPLUS
 CN 4-Isothiazolecarboxamide, 3-[(4-chloro-2,6-difluorophenyl)methoxy]-5-[[[4-(2-(hydroxymethyl)-1-pyrrolidinyl)butyl]amino]carbonylamino]- (9CI) (CA INDEX NAME)




RN 252003-80-8 HCAPLUS
 CN 4-Isothiazolecarboxamide, 3-[(2,6-difluoro-4-methylphenyl)methoxy]-5-[[[4-(2-(hydroxymethyl)-1-piperidinyl)butyl]amino]carbonylamino]- (9CI) (CA INDEX NAME)



L4 ANSWER 7 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 252003-83-1 HCAPLUS
 CN 4-Isothiazolecarboxamide, 3-[(2,5-difluoro-4-methylphenyl)methoxy]-5-[[[4-(2-(hydroxymethyl)-1-piperidinyl)butyl]amino]carbonylamino]- (9CI) (CA INDEX NAME)



RN 252003-84-2 HCAPLUS
 CN 4-Isothiazolecarboxamide, 3-[(4-chloro-2,6-difluorophenyl)methoxy]-5-[[[5-(2-(hydroxymethyl)-1-piperidinyl)hexyl]amino]carbonylamino]- (9CI) (CA INDEX NAME)

L4 ANSWER 7 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 252003-81-9 HCAPLUS
 CN 4-Isouthiazolecarboxamide, 3-[(2,5-difluoro-4-methylphenyl)methoxy]-5-[[[3-(2-(hydroxymethyl)-1-piperidinyl)propyl]amino]carbonylamino]- (9CI) (CA INDEX NAME)



PAGE 1-A


PAGE 2-A



RN 252003-82-0 HCAPLUS


CN 4-Isouthiazolecarboxamide, 3-[(4-chloro-2,6-difluorophenyl)methoxy]-5-[[[4-(2-(hydroxymethyl)-1-piperidinyl)butyl]amino]carbonylamino]- (9CI) (CA INDEX NAME)

L4 ANSWER 7 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 252003-85-3 HCAPLUS


CN 4-Isouthiazolecarboxamide, 3-[(4-bromo-2,3,6-trifluorophenyl)methoxy]-5-[[[3-(4-methyl-1-piperazinyl)propyl]amino]carbonylamino]- (9CI) (CA INDEX NAME)



RN 252003-86-4 HCAPLUS


CN 4-Isouthiazolecarboxamide, 3-[(2,6-difluoro-4-methylphenyl)methoxy]-5-[[[3-(4-methyl-1-piperazinyl)propyl]amino]carbonylamino]- (9CI) (CA INDEX NAME)

L4 ANSWER 7 OF 19 HCAPIUS COPYRIGHT 2005 ACS on STN (Continued)



RN 252003-87-5 HCAPIUS
 CN 4-Isythiazolecarboxamide, 5-[[[3-hydroxy-5-(1-pyrrolidinyl)pentyl]amino]carbonylamino]-3-[(2,3,6-trifluoro-4-methylphenyl)methoxy]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B


Me

RN 252003-88-6 HCAPIUS
 CN 4-Isythiazolecarboxamide, 3-[(4-chloro-2,6-difluorophenyl)methoxy]-5-[[[2-(1-methyl-2-pyrrolidinyl)ethyl]amino]carbonylamino]- (9CI) (CA INDEX NAME)


L4 ANSWER 7 OF 19 HCAPIUS COPYRIGHT 2005 ACS on STN (Continued)



RN 252003-92-2 HCAPIUS
 CN 4-Isythiazolecarboxamide, 3-[(4-chloro-2,6-difluorophenyl)methoxy]-5-[[[4-[2-(hydroxymethyl)-1-pyrrolidinyl]butyl]amino]carbonylamino]- (9CI) (CA INDEX NAME)




RN 252003-94-4 HCAPIUS
 CN 4-Isythiazolecarboxamide, 5-[[[3-[(1-methylethyl)amino]propyl]amino]carbonylamino]-3-[(2,3,6-trifluoro-4-methylphenyl)methoxy]- (9CI) (CA INDEX NAME)




RN 252003-95-5 HCAPIUS
 CN 4-Isythiazolecarboxamide, 5-[[[4-(4-methyl-1-piperazinyl)butyl]amino]carbonylamino]-3-[(2,3,6-trifluoro-4-methylphenyl)methoxy]- (9CI) (CA INDEX NAME)


L4 ANSWER 7 OF 19 HCAPIUS COPYRIGHT 2005 ACS on STN (Continued)



RN 252003-89-7 HCAPIUS
 CN 4-Isythiazolecarboxamide, 3-[(4-chloro-2,3,6-trifluorophenyl)methoxy]-5-[[[2-(1-methyl-2-pyrrolidinyl)ethyl]amino]carbonylamino]- (9CI) (CA INDEX NAME)




RN 252003-90-0 HCAPIUS
 CN 4-Isythiazolecarboxamide, 3-[(4-chloro-2,3,6-trifluorophenyl)methoxy]-5-[[[2-(1-methyl-2-pyrrolidinyl)ethyl]amino]carbonylamino]- (9CI) (CA INDEX NAME)




RN 252003-91-1 HCAPIUS
 CN 4-Isythiazolecarboxamide, 3-[(4-chloro-2,3,6-trifluorophenyl)methoxy]-5-[[[4-(1-pyrrolidinyl)butyl]amino]carbonylamino]- (9CI) (CA INDEX NAME)

L4 ANSWER 7 OF 19 HCAPIUS COPYRIGHT 2005 ACS on STN (Continued)




RN 252003-96-6 HCAPIUS
 CN 4-Isythiazolecarboxamide, 5-[[[3-[(1-pyrrolidinyl)propyl]amino]carbonylamino]amino]-3-[(2,3,6-trifluoro-4-methylphenyl)methoxy]- (9CI) (CA INDEX NAME)




RN 252003-97-7 HCAPIUS
 CN 4-Isythiazolecarboxamide, 5-[[[4-(4-methyl-1-piperidinyl)butyl]amino]carbonylamino]-3-[(2,3,6-trifluoro-4-methylphenyl)methoxy]- (9CI) (CA INDEX NAME)


L4 ANSWER 7 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 252003-98-8 HCAPLUS
 CN 4-Isothiazolecarboxamide, 3-[(4-chloro-2,6-difluorophenyl)methoxy]-5-[[[4-(1H-imidazol-1-yl)butyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 252003-99-9 HCAPLUS
 CN 4-Isothiazolecarboxamide, 5-[[[4-(ethyl(2-hydroxyethyl)amino)butyl]amino]carbonyl]amino]-3-[(2,3,6-trifluoro-4-methylphenyl)methoxy]- (9CI) (CA INDEX NAME)




L4 ANSWER 7 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 252004-03-8 HCAPLUS
 CN 4-Isothiazolecarboxamide, 3-[(2,6-difluoro-4-methylphenyl)methoxy]-5-[[[4-(dimethylamino)butyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 252004-04-9 HCAPLUS
 CN 4-Isothiazolecarboxamide, 3-[(2,6-difluoro-4-methylphenyl)methoxy]-5-[[[3-(dimethylamino)propyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 252004-05-0 HCAPLUS
 CN 4-Isothiazolecarboxamide, 3-[(4-chloro-2,3,6-trifluorophenyl)methoxy]-5-[[[4-(1H-imidazol-1-yl)butyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)

L4 ANSWER 7 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 252004-00-5 HCAPLUS
 CN 4-Isothiazolecarboxamide, 3-[(4-chloro-2,3,6-trifluorophenyl)methoxy]-5-[[[4-(2-hydroxymethyl)-1-piperidinyl]butyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 252004-01-6 HCAPLUS
 CN 4-Isothiazolecarboxamide, 3-[(4-chloro-2,3,6-trifluorophenyl)methoxy]-5-[[[3-hydroxy-5-(1-pyrrolidinyl)pentyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)




PAGE 1-A

PAGE 1-B


-C1

RN 252004-02-7 HCAPLUS
 CN 4-Isothiazolecarboxamide, 3-[(4-bromo-2,6-difluorophenyl)methoxy]-5-[[[3-(4-methyl-1-piperazinyl)propyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)


L4 ANSWER 7 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 252004-07-2 HCAPLUS
 CN 4-Isothiazolecarboxamide, 3-[(4-chloro-2,3,6-trifluorophenyl)methoxy]-5-[[[3-(ethyl(2-hydroxyethyl)amino)propyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 252004-08-3 HCAPLUS
 CN 4-Isothiazolecarboxamide, 5-[[[3-(methylamino)propyl]amino]carbonyl]amino]-3-[(2,3,6-trifluoro-4-methylphenyl)methoxy]- (9CI) (CA INDEX NAME)




RN 252004-09-4 HCAPLUS
 CN 4-Isothiazolecarboxamide, 5-[[[3-(4-aminopropyl)methylamino]carbonyl]amino]-3-[(2,3,6-trifluoro-4-methylphenyl)methoxy]- (9CI) (CA INDEX NAME)




RN 252004-11-8 HCAPLUS


L4 ANSWER 7 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CN 4-Isothiazolecarboxamide, 3-[(2,6-difluoro-4-methylphenyl)methoxy]-5-[[[3-(1-pyrrolidinyl)propyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 252004-12-9 HCAPLUS
 CN 4-Isouthiazolecarboxamide, 3-[(3-chloro-2,6-difluoro-4-methylphenyl)methoxy]-5-[[[4-(dimethylamino)butyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 666049-35-0 HCAPLUS
 CN 4-Isouthiazolecarboxamide, 3-[(2,5-difluoro-4-methylphenyl)methoxy]-5-[[[4-[3-(hydroxymethyl)-1-pyrrolidinyl]butyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2004:182368 HCAPLUS
 DOCUMENT NUMBER: 140:229401
 TITLE: Three hybrid assay system for isolating ligand-binding polypeptides and for isolating small mol. ligands
 INVENTOR(S): Come, Jon H.; Becker, Frank; Kley, Nikolai A.; Reichel, Christoph
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 238 pp., Cont.-in-part of U.S. Ser. No. 91,177.
 DOCUMENT TYPE: CODEN: USXXCO
 LANGUAGE: Patent
 English
 FAMILY ACC. NUM. COUNT: 6
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004043388	A1	20040304	US 2002-234985	20020903
US 2003165873	A1	20030904	US 2002-91177	20020304
US 2004266854	A1	20041230	US 2004-820453	20040407
PRIORITY APPL. INFO.:			US 2001-272932P	P 20010302
			US 2001-278233P	P 20010323
			US 2001-329437P	P 20011015
			US 2002-91177	A2 20020304
			US 2001-336962P	P 20011203
			WO 2002-US6677	A2 20020304
			US 2002-234985	A2 20020903
			WO 2002-US33052	A2 20021015
			US 2003-460921P	P 20030407
			US 2003-531872P	P 20031223

IT 252003-53-SD, conjugates
 RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (three hybrid assay system for isolating ligand-binding polypeptides and for isolating small mol. ligands)
 RN 252003-53-5 HCAPLUS
 CN 4-Isouthiazolecarboxamide, 3-[(2-fluoro-4-methylphenyl)methoxy]-5-[[[3-(4-methyl-1-piperazinyl)propyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)


L4 ANSWER 8 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



L4 ANSWER 9 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2004:162468 HCAPLUS
 DOCUMENT NUMBER: 140:217633
 TITLE: Preparation of 5-isothiazolamines as protein kinase inhibitors for treatment of cancer and hyperproliferative disorders
 INVENTOR(S): Zhang, Weijian; Ricketts, William; An, Haoyun; Hong, Zhi
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 14 pp.
 DOCUMENT TYPE: CODEN: USXXCO
 LANGUAGE: Patent
 English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004039037	A1	20040226	US 2003-455149	20030604
PRIORITY APPL. INFO.:			US 2002-386175P	P 20020604
OTHER SOURCE(S):			MARPAT 140:217633	

IT 663958-31-4P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of 5-isothiazolamines as protein kinase inhibitors for treatment of cancer and hyperproliferative disorders)
 RN 663958-31-4 HCAPLUS
 CN 4-Isouthiazolecarboxamide, 2,3-dihydro-3-oxo-5-[(4-phenoxyphenyl)amino]- (9CI) (CA INDEX NAME)




L4 ANSWER 10 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:101162 HCAPLUS
DOCUMENT NUMBER: 140:146129
TITLE: Preparation of isothiazole derivatives as anticancer agents
INVENTOR(S): Kwan, Tricia Ann; Lagreca, Susan Deborah; Lipka, Blaise Scott; Morris, Joel; Wessel, Matthew David
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 48 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004011461	A1	20040205	WO 2003-1B3161	20030714
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2493701	AA	20040205	CA 2003-2493701	20030714
BR 2003012798	A	20050503	BR 2003-12798	20030714
EP 1527071	A1	20050504	EP 2003-741009	20030714
R: AE, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2004152691	A1	20040805	US 2003-626406	20030724
PRIORITY APPLN. INFO.: US 2002-398386P P 20020725 WO 2003-1B3161 W 20030714				

OTHER SOURCE(S): MARPAT 140:146129
IT 651305-29-2P 651305-30-5P 651305-31-6P
651305-33-8P 651305-34-9P 651305-35-0P
651305-36-1P 651305-37-2P 651305-38-3P
651305-39-4P 651305-40-7P 651305-42-9P
651305-43-0P 651305-44-1P 651305-45-2P
651305-46-3P 651305-47-4P 651305-48-5P
651305-49-6P 651305-50-9P 651305-51-0P
651305-52-1P 651305-53-2P 651305-54-3P
651305-55-4P 651305-56-5P 651305-57-6P
651305-58-7P 651305-59-8P 651305-60-1P
651305-61-2P 651305-62-3P 651305-63-4P
651305-64-5P 651305-65-6P 651305-66-7P
651305-67-8P 651305-68-9P 651305-69-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of isothiazole derivs. as anticancer agents)
RN 651305-29-2 HCAPLUS
CN 4-Isythiazolecarboxamide, 3-(cyclohexylmethoxy)-5-(pyrazinylamino)- (9CI) (CA INDEX NAME)


L4 ANSWER 10 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 651305-30-5 HCAPLUS
CN 4-Isythiazolecarboxamide, 3-(cyclohexylmethoxy)-5-(4-pyrimidinylamino)- (9CI) (CA INDEX NAME)




RN 651305-31-6 HCAPLUS
CN 4-Isythiazolecarboxamide, 3-(cyclohexylmethoxy)-5-(2-pyrimidinylamino)- (9CI) (CA INDEX NAME)



RN 651305-33-8 HCAPLUS
CN Formic acid, compd. with 3-(cyclohexylmethoxy)-5-[(3-hydroxy-2-pyridinyl)amino]-4-isythiazolecarboxamide (1:1) (9CI) (CA INDEX NAME)
CH 1
CRN 651305-32-7
CMF C16 H20 N4 O3 S


L4 ANSWER 10 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



CH 2
CRN 64-18-6
CMF C H2 O2


O=CH-OH

RN 651305-34-9 HCAPLUS
CN 4-Isythiazolecarboxamide, 3-(cyclohexylmethoxy)-5-[(5-fluoro-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 651305-35-0 HCAPLUS
CN 4-Isythiazolecarboxamide, 3-(cyclohexylmethoxy)-5-(2-pyridinylamino)- (9CI) (CA INDEX NAME)


L4 ANSWER 10 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 651305-36-1 HCAPLUS
CN 4-Isythiazolecarboxamide, 3-(cyclohexylmethoxy)-5-[(3-methyl-2-pyridinyl)amino]- (9CI) (CA INDEX NAME)




RN 651305-37-2 HCAPLUS
CN 4-Isythiazolecarboxamide, 3-(cyclohexylmethoxy)-5-(3-pyridinylamino)- (9CI) (CA INDEX NAME)




RN 651305-38-3 HCAPLUS
CN 4-Isythiazolecarboxamide, 3-(cyclohexylmethoxy)-5-(4-pyridinylamino)- (9CI) (CA INDEX NAME)


L4 ANSWER 10 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 651305-39-4 HCAPLUS
 CN 4-Isythiazolecarboxamide, 3-(cyclohexylmethoxy)-5-[(2,6-dimethyl-4-pyrimidinyl)amino]- (9CI) (CA INDEX NAME)




RN 651305-40-7 HCAPLUS
 CN 4-Isythiazolecarboxamide, 3-(cyclohexylmethoxy)-5-(1H-pyrazol-3-ylamino)- (9CI) (CA INDEX NAME)




RN 651305-42-9 HCAPLUS
 CN Formic acid, compd. with 5-(1H-benzimidazol-2-ylamino)-3-(cyclohexylmethoxy)-4-isythiazolecarboxamide (1:1) (9CI) (CA INDEX NAME)


L4 ANSWER 10 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 651305-45-2 HCAPLUS
 CN 4-Isythiazolecarboxamide, 3-[(cyclohexylmethyl)thio]-5-(3-pyridinylamino)- (9CI) (CA INDEX NAME)




RN 651305-46-3 HCAPLUS
 CN 4-Isythiazolecarboxamide, 3-[[1-(4-chlorophenyl)ethyl]thio]-5-(3-pyridinylamino)- (9CI) (CA INDEX NAME)



RN 651305-47-4 HCAPLUS
 CN 4-Isythiazolecarboxamide, 3-[[1-(4-chlorophenyl)ethyl]thio]-5-(4-pyridinylamino)- (9CI) (CA INDEX NAME)

L4 ANSWER 10 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)


CM 1
 CRN 651305-41-8
 CMF C18 H21 N5 O2 S



CM 2
 CRN 64-18-6
 CMF C H2 O2


O=CH-OH

RN 651305-43-0 HCAPLUS
 CN 4-Isythiazolecarboxamide, 3-[[1-(4-chlorophenyl)methyl]thio]-5-(3-pyridinylamino)- (9CI) (CA INDEX NAME)




RN 651305-44-1 HCAPLUS
 CN 4-Isythiazolecarboxamide, 3-[[1-(4-chlorophenyl)propyl]thio]-5-(3-pyridinylamino)- (9CI) (CA INDEX NAME)


L4 ANSWER 10 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 651305-48-5 HCAPLUS
 CN 4-Isythiazolecarboxamide, 3-[[1-(4-chlorophenyl)methyl]thio]-5-(4-pyridinylamino)- (9CI) (CA INDEX NAME)




RN 651305-49-6 HCAPLUS
 CN 4-Isythiazolecarboxamide, 3-[[1-(4-chlorophenyl)methyl]thio]-5-[(6-methoxy-3-pyridinyl)amino]- (9CI) (CA INDEX NAME)




RN 651305-50-9 HCAPLUS
 CN 4-Isythiazolecarboxamide, 3-(hexylthio)-5-(4-pyridinylamino)- (9CI) (CA INDEX NAME)


L4 ANSWER 10 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 651305-51-0 HCAPLUS
 CN 4-Isothiazolecarboxamide, 3-(cyclohexylthio)-5-(4-pyridinylamino)- (9CI)
 (CA INDEX NAME)




RN 651305-52-1 HCAPLUS
 CN 4-Isothiazolecarboxamide, 3-[(2-phenylethyl)thio]-5-(4-pyridinylamino)- (9CI)
 (CA INDEX NAME)




RN 651305-53-2 HCAPLUS
 CN 4-Isothiazolecarboxamide, 3-[[4-(4-chlorophenyl)methyl]thio]-5-(4-pyrimidinylamino)- (9CI)
 (CA INDEX NAME)


L4 ANSWER 10 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 651305-57-6 HCAPLUS
 CN 4-Isothiazolecarboxamide, 3-[[3,5-dimethoxyphenyl]methyl]thio]-5-(3-pyridinylamino)- (9CI)
 (CA INDEX NAME)




RN 651305-58-7 HCAPLUS
 CN 4-Isothiazolecarboxamide, 5-(3-pyridinylamino)-3-[[4-(trifluoromethyl)phenyl]methyl]thio]- (9CI)
 (CA INDEX NAME)




RN 651305-59-8 HCAPLUS
 CN 4-Isothiazolecarboxamide, 5-(3-pyridinylamino)-3-[[2-(trifluoromethyl)phenyl]methyl]thio]- (9CI)
 (CA INDEX NAME)


L4 ANSWER 10 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 651305-54-3 HCAPLUS
 CN 4-Isouthiazolecarboxamide, 3-[[4-(4-chlorophenyl)methyl]thio]-5-(pyrazinylamino)- (9CI)
 (CA INDEX NAME)




RN 651305-55-4 HCAPLUS
 CN 4-Isouthiazolecarboxamide, 3-[(1-phenylethyl)thio]-5-(3-pyridinylamino)- (9CI)
 (CA INDEX NAME)




RN 651305-56-5 HCAPLUS
 CN 4-Isouthiazolecarboxamide, 3-[[2-(4-chlorophenyl)methyl]thio]-5-(3-pyridinylamino)- (9CI)
 (CA INDEX NAME)


L4 ANSWER 10 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 651305-60-1 HCAPLUS
 CN 4-Isouthiazolecarboxamide, 3-[(1-phenylpropyl)thio]-5-(3-pyridinylamino)- (9CI)
 (CA INDEX NAME)




RN 651305-61-2 HCAPLUS
 CN 4-Isouthiazolecarboxamide, 3-[[4-(4-chlorophenyl)methyl]thio]-5-(2-pyridinylamino)- (9CI)
 (CA INDEX NAME)




RN 651305-62-3 HCAPLUS
 CN 4-Isouthiazolecarboxamide, 3-[[4-(4-chlorophenyl)methyl]thio]-5-(2-pyrimidinylamino)- (9CI)
 (CA INDEX NAME)


L4 ANSWER 10 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 651305-63-4 HCAPLUS
 CN 4-Isothiazolecarboxamide, 3-[[1-(4-chlorophenyl)methyl]thio]-5-[(6-methoxy-2-pyridinyl)amino]- (9CI) (CA INDEX NAME)




RN 651305-64-5 HCAPLUS
 CN 4-Isothiazolecarboxamide, 3-[[1-(4-chlorophenyl)propyl]thio]-5-[(5-methyl-2-pyridinyl)amino]- (9CI) (CA INDEX NAME)




RN 651305-65-6 HCAPLUS
 CN 4-Isothiazolecarboxamide, 3-[[1-(4-chlorophenyl)propyl]thio]-5-[(6-methyl-2-pyridinyl)amino]- (9CI) (CA INDEX NAME)


L4 ANSWER 10 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 651305-69-0 HCAPLUS
 CN 4-Isothiazolecarboxamide, 3-[[1-(4-chlorophenyl)propyl]thio]-5-[(5-pyrimidinylamino)- (9CI) (CA INDEX NAME)




IT 651305-74-7P 651305-75-8P 651305-79-2P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of isothiazole derivs. as anticancer agents)
 RN 651305-74-7 HCAPLUS
 CN 4-Isothiazolecarboxamide, 3-(methylthio)-5-(4-pyridinylamino)- (9CI) (CA INDEX NAME)




RN 651305-75-8 HCAPLUS
 CN 4-Isothiazolecarboxamide, 3-(methylsulfonyl)-5-(4-pyridinylamino)- (9CI) (CA INDEX NAME)


L4 ANSWER 10 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 651305-66-7 HCAPLUS
 CN 4-Isothiazolecarboxamide, 3-[[1-(4-chlorophenyl)propyl]thio]-5-[(3-methyl-2-pyridinyl)amino]- (9CI) (CA INDEX NAME)




RN 651305-67-8 HCAPLUS
 CN 4-Isothiazolecarboxamide, 3-[[1-(4-chlorophenyl)propyl]thio]-5-[(2-(1-methylethyl)-4-pyridinyl)amino]- (9CI) (CA INDEX NAME)




RN 651305-68-9 HCAPLUS
 CN 4-Isothiazolecarboxamide, 3-[[1-(4-chlorophenyl)propyl]thio]-5-[(6-methyl-3-pyridinyl)amino]- (9CI) (CA INDEX NAME)

L4 ANSWER 10 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 651305-79-2 HCAPLUS
 CN 4-Isothiazolecarboxamide, 2,3-dihydro-5-(3-pyridinylamino)-3-thioxo- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 19 HCAPIUS COPYRIGHT 2005 ACS ON STN

ACCESSION NUMBER: 2003:885654 HCAPIUS
DOCUMENT NUMBER: 140:138923
TITLE: Pharmacological Characterization of CP-547,632, a Novel Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase Inhibitor for Cancer Therapy
AUTHOR(S): Beebe, Jean S.; Jani, Jitesh P.; Knauth, Elisabeth; Goodwin, Peter; Higdon, Carla; Rossi, Ann Marie; Emerson, Erling; Finkelstein, Martin; Floyd, Eugenia; Harriman, Shawn; Atherton, Jim; Hillerman, Steve; Soderstrom, Cathy; Kou, Kou; Gant, Tom; Noe, Mark C.; Foster, Barb; Rastinejad, Farzan; Marx, Matthew A.; Schaeffer, Tracey; Whalen, Pamela M.; Roberts, W. Gregory
CORPORATE SOURCE: Cancer Drug Discovery, Pfizer Global Research and Development, Groton, CT, 06340, USA
SOURCE: Cancer Research (2003), 63(21), 7301-7309
CODEN: CNREAS; ISSN: 0008-5472
PUBLISHER: American Association for Cancer Research
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 252003-65-9, CP-547632
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmacol. characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy)
RN 252003-65-9 HCAPIUS
CN 4-Isothiazolecarboxamide, 3-[(4-bromo-2,6-difluorophenyl)methoxy]-5-[[[(4-(1-pyrrolidinyl)butyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 12 OF 19 HCAPIUS COPYRIGHT 2005 ACS ON STN

ACCESSION NUMBER: 2003:719299 HCAPIUS
DOCUMENT NUMBER: 139:240339
TITLE: Antitumor agent comprising combination of sulfonamide-containing heterocyclic compound with angiogenesis inhibitor
INVENTOR(S): Wakabayashi, Toshiaki; Ono, Naoto; Semba, Taro; Haneda, Toru
PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan
SOURCE: PCT Int. Appl., 49 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003074045	A1	20030912	WO 2003-JP2492	20030304
M: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1481678	A1	20041201	EP 2003-743594	20030304
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2005119303	A1	20050602	US 2003-504676	20030304
PRIORITY APPLN. INFO.: JP 2002-59471 A 20020305 WO 2003-JP2492 W 20030304				


OTHER SOURCE(S): MARPAT 139:240339
IT 252003-65-9, CP 547632
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antitumor agent comprising combination of sulfonamide-containing heterocyclic compound with angiogenesis inhibitor)
RN 252003-65-9 HCAPIUS
CN 4-Isouthiazolecarboxamide, 3-[(4-bromo-2,6-difluorophenyl)methoxy]-5-[[[(4-(1-pyrrolidinyl)butyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 12 OF 19 HCAPIUS COPYRIGHT 2005 ACS ON STN (Continued)

L4 ANSWER 13 OF 19 HCAPIUS COPYRIGHT 2005 ACS ON STN
ACCESSION NUMBER: 2002:835622 HCAPIUS
DOCUMENT NUMBER: 139:6778
TITLE: Product class 15: isothiazoles
AUTHOR(S): Brown, D. W.; Sainsbury, M.
CORPORATE SOURCE: Germany
SOURCE: Science of Synthesis (2002), 11, 507-572
CODEN: SSCTJ9
PUBLISHER: Georg Thieme Verlag
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
IT 1141-16-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of isothiazoles via oxidative ring closure of 3-aminopropenethionamides or 3-aminoprop-2-enethionones)
RN 1141-16-8 HCAPIUS
CN 4-Isouthiazolecarboxamide, 2,3-dihydro-3-oxo-5-(phenylamino)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 286 THERE ARE 286 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:42887 HCAPLUS
DOCUMENT NUMBER: 137:24295

TITLE: Salts of an isothiazole-4-carboxamide derivative, namely 3-[(4-bromo-2,6-difluorobenzoyloxy)-5-[(4-pyrrolidin-1-yl)butyl]ureido]isothiazole-4-carboxylic acid amide, and their use as anti-hyperproliferation agents

INVENTOR(S): Gent, Thomas G.; Williams, Glenn Robert

PATENT ASSIGNEE(S): Pfizer Products Inc., USA

SOURCE: PCT Int. Appl., 38 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002/044158	A1	20020606	WO 2001-182193	20011119
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2430065	AA	20020606	CA 2001-2430065	20011119
AU 2002014204	A5	20020611	AU 2002-14204	20011119
EP 137521	A1	20030827	EP 2001-982663	20011119
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001015621	A	20030902	BR 2001-15621	20011119
EE 200300247	A	20031015	EE 2003-247	20011119
JP 2004514714	T2	20040520	JP 2002-546528	20011119
NZ 525788	A	20041126	NZ 2001-525788	20011119
US 2002151573	A1	20041017	US 2001-993640	20011127
US 6831091	B2	20041214		
BG 107752	A	20040130	BG 2003-107752	20030422
ZA 2003003341	A	20040430	ZA 2003-3341	20030430
HR 2003000408	A1	20030831	HR 2003-408	20030520
NO 2003002388	A	20030718	NO 2003-2388	20030527
PRIORITY APPLN. INFO.: US 2000-253513P P 20001128				
WO 2001-182193 W 20011119				


IT 252003-66-0P, 3-[(4-bromo-2,6-difluorobenzoyloxy)-5-[(4-pyrrolidin-1-yl)butyl]ureido]isothiazole-4-carboxylic acid amide mesylate
 252003-71-7P, 3-[(4-bromo-2,6-difluorobenzoyloxy)-5-[(4-pyrrolidin-1-yl)butyl]ureido]isothiazole-4-carboxylic acid amide hydrochloride (1:1) 433978-97-3P, 3-[(4-bromo-2,6-difluorobenzoyloxy)-5-[(4-pyrrolidin-1-yl)butyl]ureido]isothiazole-4-carboxylic acid amide hydrobromide (1:1) 433978-98-4P, 3-[(4-bromo-2,6-difluorobenzoyloxy)-5-[(4-pyrrolidin-1-yl)butyl]ureido]isothiazole-4-carboxylic acid amide hemisulfate 433978-99-5P, 3-[(4-bromo-2,6-difluorobenzoyloxy)-5-[(4-pyrrolidin-1-yl)butyl]ureido]isothiazole-4-carboxylic acid amide acetate 433979-00-1P, 3-[(4-bromo-2,6-difluorobenzoyloxy)-5-[(4-pyrrolidin-1-yl)butyl]ureido]isothiazole-4-carboxylic acid amide

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl


RN 433978-97-3 HCAPLUS
 CN 4-Isithiazolecarboxamide, 3-[(4-bromo-2,6-difluorophenyl)methoxy]-5-[[[4-(1-pyrrolidinyl)butyl]amino]carbonyl]amino]-, monohydrobromide (9CI) (CA INDEX NAME)



● HBr

RN 433978-98-4 HCAPLUS
 CN 4-Isithiazolecarboxamide, 3-[(4-bromo-2,6-difluorophenyl)methoxy]-5-[[[4-(1-pyrrolidinyl)butyl]amino]carbonyl]amino]-, 2-hydroxy-1,2,3-propanetricarboxylate (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 252003-65-9
CMF C20 H24 Br F2 N5 O3 S

CM 2

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

p-tosylate 433979-01-2P, 3-[(4-bromo-2,6-difluorobenzoyloxy)-5-[(4-pyrrolidin-1-yl)butyl]ureido]isothiazole-4-carboxylic acid amide L-tartrate 433979-02-3P, 3-[(4-bromo-2,6-difluorobenzoyloxy)-5-[(4-pyrrolidin-1-yl)butyl]ureido]isothiazole-4-carboxylic acid amide hemisulfate


RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. and X-ray powder diffraction spectra of pharmaceutical salts of (bromodifluorobenzoyloxy) [(pyrrolidinyl)butyl]ureido]isothiazolecarboxamide for use as antihyperproliferatives)

RN 252003-66-0 HCAPLUS
 CN 4-Isithiazolecarboxamide, 3-[(4-bromo-2,6-difluorophenyl)methoxy]-5-[[[4-(1-pyrrolidinyl)butyl]amino]carbonyl]amino]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 252003-65-9

CMF C20 H24 Br F2 N5 O3 S



CM 2


CRN 75-75-2

CMF C H4 O3 S



RN 252003-71-7 HCAPLUS
 CN 4-Isithiazolecarboxamide, 3-[(4-bromo-2,6-difluorophenyl)methoxy]-5-[[[4-(1-pyrrolidinyl)butyl]amino]carbonyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)


CRN 71-92-9
CMF C6 H8 O7

RN 433978-99-5 HCAPLUS
 CN 4-Isithiazolecarboxamide, 3-[(4-bromo-2,6-difluorophenyl)methoxy]-5-[[[4-(1-pyrrolidinyl)butyl]amino]carbonyl]amino]-, monoacetate (9CI) (CA INDEX NAME)

CM 1

CRN 252003-65-9

CMF C20 H24 Br F2 N5 O3 S



CM 2

CRN 64-19-7

CMF C2 H4 O2




RN 433979-00-1 HCAPLUS
 CN 4-Isithiazolecarboxamide, 3-[(4-bromo-2,6-difluorophenyl)methoxy]-5-[[[4-(1-pyrrolidinyl)butyl]amino]carbonyl]amino]-, mono(4-methylbenzenesulfonate) (9CI) (CA INDEX NAME)

CM 1


CRN 252003-65-9

CMF C20 H24 Br F2 N5 O3 S

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




CM 2

CRN 104-15-4
CMF C7 H8 O3 S

RN 433979-01-2 HCAPLUS
CN 4-isothiazolecarboxamide, 3-[(4-bromo-2,6-difluorophenyl)methoxy]-5-[[[4-(1-pyrrolidinyl)butyl]amino]carbonyl]amino]-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 252003-65-9
CMF C20 H24 Br F2 N5 O3 S

CM 2

CRN 87-69-4
CMF C4 H6 O6


Absolute stereochemistry.

L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 433979-02-3 HCAPLUS

CN Butanedioic acid, compd. with 3-[(4-bromo-2,6-difluorophenyl)methoxy]-5-[[[4-(1-pyrrolidinyl)butyl]amino]carbonyl]amino]-4-isothiazolecarboxamide (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 252003-65-9
CMF C20 H24 Br F2 N5 O3 S

CM 2

CRN 110-15-6
CMF C4 H6 O4

IT 252003-65-9, 3-[(4-Bromo-2,6-difluorobenzyl)oxy]-5-[3-[4-(pyrrolidin-1-yl)butyl]ureido]isothiazole-4-carboxylic acid amide
RL: FRP (Properties); RCT (Reactant); RACT (Reactant or reagent)
(preparation and X-ray powder diffraction spectra of pharmaceutical salts of (bromodifluorobenzyl)oxy[(pyrrolidinyl)butyl]ureido]isothiazolecarboxamide for use as antihyperproliferatives)

RN 252003-65-9 HCAPLUS

CN 4-isothiazolecarboxamide, 3-[(4-bromo-2,6-difluorophenyl)methoxy]-5-[[[4-(1-pyrrolidinyl)butyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)

L4 ANSWER 15 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN


ACCESSION NUMBER: 2000-842124 HCAPLUS
DOCUMENT NUMBER: 134:17396
TITLE: Preparation of thiophene-3-carboxamides as anticancer agents
INVENTOR(S): Gant, Thomas George; Noe, Mark Carl
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 35 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000071532	A1	20001130	WO 2000-1B570	20000503
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6380214	B1	20020430	US 2000-549893	20000417
CA 2374247	AA	20001130	CA 2000-2374247	20000503
BR 2000010746	A	20020213	BR 2000-10746	20000503
EP 1187826	A1	20020320	EP 2000-920969	20000503
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2003500401	T2	20030107	JP 2000-619789	20000503
JP 3692041	B2	20050907		
JP 2005008641	A2	20050113	JP 2004-211640	20040720
PRIORITY APPLN. INFO.:			US 1999-134933P	P 19990519
			JP 2000-619789	A3 20000503
			WO 2000-1B570	W 20000503

OTHER SOURCE(S): MARPAT 134:17396
IT 309278-84-OP 309278-85-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of thiophene-3-carboxamides as anticancer agents)

RN 309278-84-0 HCAPLUS


CN 4-isothiazolecarboxamide, 5-(benzoylamino)-3-(pentylthio)- (9CI) (CA INDEX NAME)



RN 309278-85-1 HCAPLUS

CN 4-isothiazolecarboxamide, 5-(benzoylamino)-3-(pentylthio)- (9CI) (CA INDEX NAME)

L4 ANSWER 15 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 16 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1999:784087 HCAPLUS
DOCUMENT NUMBER: 132:22961
TITLE: Preparation of isothiazolamide urea derivatives as anticancer agents
INVENTOR(S): Larson, Eric Robert; Noe, Mark Carl; Gant, Thomas George
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 132 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9962890	A1	19991209	WO 1999-18797	19990503
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, US, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2333703	AA	19991209	CA 1999-2333703	19990503
CA 2333703	C	20050614		
CA 2475113	AA	19991209	CA 1999-2475113	19990503
AU 9933421	A1	19991220	AU 1999-33421	19990503
BR 9910900	A	20010213	BR 1999-10900	19990503
EP 1084114	A1	20010321	EP 1999-914724	19990503
EP 1084114	B1	20040908		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
TR 200003478	T2	20010321	TR 2000-200003478	19990503
JP 2002517384	T2	20020618	JP 2000-552102	19990503
NZ 507009	A	20031128	NZ 1999-507009	19990503
AT 275553	E	20040915	AT 1999-914724	19990503
PT 1084114	T	20041231	PT 1999-914724	19990503
ES 2226368	T3	20050316	ES 1999-914724	19990503
US 6235764	B1	20010522	US 1999-316837	19990521
TW 561154	B	20031111	TW 1999-88108991	19990531
ZA 9903752	A	20001204	ZA 1999-3752	19990603
BG 104998	A	20010731	BG 2000-104998	20001128
NO 2000006071	A	20001130	NO 2000-6071	20001130
HR 2000000835	A1	20011231	HR 2000-835	20001204
US 2001020034	A1	20010906	US 2001-803296	20010309
US 6548526	B2	20030415		
HK 1036982	A1	20050401	HK 2001-107830	20011108
US 2003149048	A1	20030807	US 2003-357093	20030203
JP 2005002122	A2	20050106	JP 2004-209396	20040716
PRIORITY APPLN. INFO.:				
			US 1998-87963P	P 19980604
			CA 1999-2333703	A3 19990503
			JP 2000-552102	A3 19990503
			WO 1999-18797	W 19990503
			US 1999-316837	A3 19990521
			US 2001-803296	A3 20010309


OTHER SOURCE(S): MARPAT 132:22961

L4 ANSWER 16 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)


IT 252004-19-6P 252004-20-9P 252004-22-1P
252004-26-5P 252004-30-1P 252004-31-2P
252004-46-9P 252004-47-0P 252004-48-1P
252004-56-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(Intermediate; preparation of isothiazolamide urea derivs. as anticancer agents and for the treatment of disorders related to vasculogenesis and/or angiogenesis)
RN 252004-19-6 HCAPLUS
CN 4-isothiazolecarboxamide, 5-amino-3-(pentylthio)- (9CI) (CA INDEX NAME)



RN 252004-20-9 HCAPLUS
CN Carbamic acid, [4-(aminocarbonyl)-3-(pentylthio)-5-isothiazolyl]-, phenyl ester (9CI) (CA INDEX NAME)




RN 252004-22-1 HCAPLUS
CN 4-isothiazolecarboxamide, 5-[[[(dimethylamino)carbonyl]amino]-2,3-dihydro-3-oxo- (9CI) (CA INDEX NAME)




RN 252004-26-5 HCAPLUS
CN Carbamic acid, [4-(aminocarbonyl)-2,3-dihydro-3-thioxo-5-isothiazolyl]-, phenyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 16 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 252004-30-1 HCAPLUS
CN Carbamic acid, [4-(aminocarbonyl)-2,3-dihydro-3-oxo-5-isothiazolyl]-, phenyl ester (9CI) (CA INDEX NAME)



RN 252004-31-2 HCAPLUS
CN Carbamic acid, [4-(aminocarbonyl)-3-[(2,6-difluoro-4-methylphenyl)methoxy]-5-isothiazolyl]-, phenyl ester (9CI) (CA INDEX NAME)




RN 252004-46-9 HCAPLUS
CN Carbamic acid, [4-(aminocarbonyl)-3-[(2,5-difluoro-4-methylphenyl)methoxy]-5-isothiazolyl]-, phenyl ester (9CI) (CA INDEX NAME)




RN 252004-47-0 HCAPLUS
CN Carbamic acid, [4-(aminocarbonyl)-3-[(2,3-difluoro-4-methylphenyl)methoxy]-5-isothiazolyl]-, phenyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 16 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 252004-48-1 HCAPLUS
 CN Carbamic acid, [4-(aminocarbonyl)-3-[(4-chloro-2,5-difluorophenyl)methoxy]-5-isothiazolyl]-, phenyl ester (9CI) (CA INDEX NAME)




RN 252004-56-1 HCAPLUS
 CN Carbamic acid, [4-(aminocarbonyl)-3-[(4-chloro-2,6-difluorophenyl)methoxy]-5-isothiazolyl]-, phenyl ester (9CI) (CA INDEX NAME)




IT 252004-58-3 252004-60-7 252004-61-8
 252004-63-0 252004-66-3
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (starting material; preparation of isothiazolamide urea derivs. as anticancer agents and for the treatment of disorders related to vasculogenesis and/or angiogenesis)
 RN 252004-58-3 HCAPLUS
 CN Carbamic acid, [4-(aminocarbonyl)-3-[(2-fluoro-4-methylphenyl)methoxy]-5-isothiazolyl]-, phenyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 16 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 252004-66-3 HCAPLUS
 CN Carbamic acid, [4-(aminocarbonyl)-3-[(3-chloro-2,6-difluoro-4-methylphenyl)methoxy]-5-isothiazolyl]-, phenyl ester (9CI) (CA INDEX NAME)




IT 252003-27-3P 252003-28-4P 252003-29-5P
 252003-30-8P 252003-32-0P 252003-33-1P
 252003-36-4P 252003-37-5P 252003-39-7P
 252003-40-0P 252003-41-1P 252003-42-2P
 252003-44-4P 252003-45-5P 252003-47-7P
 252003-49-9P 252003-50-2P 252003-51-3P
 252003-52-4P 252003-53-5P 252003-54-6P
 252003-55-7P 252003-56-8P 252003-57-9P
 252003-58-0P 252003-59-1P 252003-60-4P
 252003-61-5P 252003-62-6P 252003-63-7P
 252003-64-8P 252003-65-9P 252003-66-0P
 252003-67-1P 252003-68-2P 252003-69-3P
 252003-70-6P 252003-71-7P 252003-72-8P
 252003-73-9P 252003-74-0P 252003-75-1P
 252003-76-2P 252003-77-3P 252003-78-4P
 252003-79-5P 252003-80-8P 252003-81-9P
 252003-82-0P 252003-83-1P 252003-84-2P
 252003-85-3P 252003-86-4P 252003-87-5P
 252003-88-6P 252003-89-7P 252003-90-0P
 252003-91-1P 252003-92-2P 252003-93-3P
 252003-94-4P 252003-95-5P 252003-96-6P
 252003-97-7P 252003-98-8P 252003-99-9P
 252004-00-5P 252004-01-6P 252004-02-7P
 252004-03-8P 252004-04-9P 252004-05-0P
 252004-07-2P 252004-08-3P 252004-09-4P
 252004-10-7P 252004-11-8P 252004-12-9P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (target compound; preparation of isothiazolamide urea derivs. as anticancer agents and for the treatment of disorders related to vasculogenesis and/or angiogenesis)
 RN 252003-27-3 HCAPLUS


L4 ANSWER 16 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 252004-60-7 HCAPLUS
 CN Carbamic acid, [4-(aminocarbonyl)-3-[(4-bromo-2,6-difluorophenyl)methoxy]-5-isothiazolyl]-, phenyl ester (9CI) (CA INDEX NAME)




RN 252004-61-8 HCAPLUS
 CN Carbamic acid, [4-(aminocarbonyl)-3-[(4-bromo-2,3,6-trifluorophenyl)methoxy]-5-isothiazolyl]-, phenyl ester (9CI) (CA INDEX NAME)




RN 252004-63-0 HCAPLUS
 CN Carbamic acid, [4-(aminocarbonyl)-3-[(2,3,6-trifluoro-4-methylphenyl)methoxy]-5-isothiazolyl]-, phenyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 16 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)


CN 4-Isothiazolecarboxamide, 5-[[[(dimethylamino)carbonyl]amino]-3-(hexylthio)- (9CI) (CA INDEX NAME)



RN 252003-28-4 HCAPLUS
 CN 4-Isouthiazolecarboxamide, 3-(pentylthio)-5-[[[(3-(1-pyrrolidinyl)propyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 252003-29-5 HCAPLUS
 CN 4-Isouthiazolecarboxamide, 5-[[[(dimethylamino)carbonyl]amino]-3-(heptyloxy)- (9CI) (CA INDEX NAME)




RN 252003-30-8 HCAPLUS
 CN 4-Isouthiazolecarboxamide, 5-[[[(3-chloro-4-fluorophenyl)methyl]amino]carbonyl]amino]-3-[[4-methylphenyl]methyl]thio]- (9CI) (CA INDEX NAME)

L4 ANSWER 16 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 252003-32-0 HCAPLUS
 CN 4-Isothiazolecarboxamide, 3-[(2,5-difluoro-4-methylphenyl)methoxy]-5-[[[4-(1-pyrrolidinyl)butyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 252003-33-1 HCAPLUS
 CN 4-Isothiazolecarboxamide, 3-[(2,5-difluoro-4-methylphenyl)methoxy]-5-[[[4-(2S)-2-(hydroxymethyl)-1-piperidinyl]butyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)


L4 ANSWER 16 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 252003-39-7 HCAPLUS
 CN 4-Isothiazolecarboxamide, 3-[(2,5-difluoro-4-methylphenyl)methoxy]-5-[[[4-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]butyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 252003-40-0 HCAPLUS
 CN 4-Isothiazolecarboxamide, 3-[(2,5-difluoro-4-methylphenyl)methoxy]-5-[[[4-(3-hydroxy-1-piperidinyl)butyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 252003-41-1 HCAPLUS
 CN 4-Isothiazolecarboxamide, 3-[(2,5-difluoro-4-methylphenyl)methoxy]-5-[[[5-[(1-methylethyl)amino]pentyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)




L4 ANSWER 16 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 252003-36-4 HCAPLUS
 CN 4-Isothiazolecarboxamide, 3-[(2,5-difluoro-4-methylphenyl)methoxy]-5-[[[4-[(3R)-3-hydroxy-1-pyrrolidinyl]butyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252003-37-5 HCAPLUS
 CN 4-Isothiazolecarboxamide, 3-[(2,5-difluoro-4-methylphenyl)methoxy]-5-[[[6-(dimethylamino)hexyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)




L4 ANSWER 16 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 252003-42-2 HCAPLUS
 CN 4-Isothiazolecarboxamide, 3-[(2,3-difluoro-4-methylphenyl)methoxy]-5-[[[4-(3,4-dihydroxy-1-pyrrolidinyl)butyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 252003-44-4 HCAPLUS
 CN 4-Isothiazolecarboxamide, 3-[(4-chloro-2,6-difluorophenyl)methoxy]-5-[[[3-hydroxy-5-(1-pyrrolidinyl)pentyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

Cl


RN 252003-45-5 HCAPLUS
 CN 4-Isothiazolecarboxamide, 3-[(4-chloro-2,6-difluorophenyl)methoxy]-5-[[[3-hydroxy-5-(1-pyrrolidinyl)pentyl]amino]carbonyl]amino]-, monomethanesulfonate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 252003-44-4
 CMF C21 H26 Cl F2 N5 O4 S

L4 ANSWER 16 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B

Cl

CH 2


CRN 75-75-2

CMF C H4 O3 S




RN 252003-47-7 HCAPLUS

CN 4-Isythiazolecarboxamide, 3-[[[4-[(bis(2-hydroxyethyl)amino)butyl]amino]carbonyl]amino]-3-[(2,5-difluoro-4-methylphenyl)methoxy]- (9CI) (CA INDEX NAME)




RN 252003-49-9 HCAPLUS

CN 4-Isythiazolecarboxamide, 3-[(2,5-difluoro-4-methylphenyl)methoxy]-5-[[[4-[(1,1-dimethylethyl)amino]-3-hydroxybutyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)

L4 ANSWER 16 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN 4-Isythiazolecarboxamide, 3-[(2,5-difluoro-4-methylphenyl)methoxy]-5-[[[6-[(2-hydroxyethyl)-1-piperazinyl]hexyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)

RN 252003-53-5 HCAPLUS


CN 4-Isythiazolecarboxamide, 3-[(2-fluoro-4-methylphenyl)methoxy]-5-[[[3-(4-methyl-1-piperazinyl)propyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 252003-54-6 HCAPLUS


CN 4-Isythiazolecarboxamide, 3-[(2,6-difluoro-4-methylphenyl)methoxy]-5-[[[4-(1-pyrrolidinyl)butyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)

L4 ANSWER 16 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 252003-50-2 HCAPLUS

CN 4-Isythiazolecarboxamide, 3-[[[4-(chloro-2,6-difluorophenyl)methoxy]-5-[[[3-(4-methyl-1-piperazinyl)propyl]amino]carbonyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)




RN 252003-51-3 HCAPLUS

CN 4-Isythiazolecarboxamide, 3-[(4-chloro-2,6-difluorophenyl)methoxy]-5-[[[3-(1-methylethyl)amino]pentyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 252003-52-4 HCAPLUS

L4 ANSWER 16 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 252003-55-7 HCAPLUS


CN 4-Isythiazolecarboxamide, 3-[(2,6-difluoro-4-methylphenyl)methoxy]-5-[[[3-(4-methyl-1-piperazinyl)butyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 252003-56-8 HCAPLUS

CN 4-Isythiazolecarboxamide, 3-[(2,6-difluoro-4-methylphenyl)methoxy]-5-[[[3-(4-methyl-1-piperazinyl)butyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)

PAGE 1-A




L4 ANSWER 16 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)


PAGE 1-B

Me


RN 252003-57-9 HCAPLUS
 CN 4-Isothiazolecarboxamide, 5-[[[4-(1-pyrrolidinyl)butyl]amino]carbonyl]amino]-3-[(2,3,6-trifluoro-4-methylphenyl)methoxy]- (9CI) (CA INDEX NAME)



RN 252003-58-0 HCAPLUS
 CN 4-Isothiazolecarboxamide, 5-[[[2-(1-methyl-2-pyrrolidinyl)ethyl]amino]carbonyl]amino]-3-[(2,3,6-trifluoro-4-methylphenyl)methoxy]- (9CI) (CA INDEX NAME)




RN 252003-59-1 HCAPLUS
 CN 4-Isothiazolecarboxamide, 5-[[[4-(dimethylamino)butyl]amino]carbonyl]amino]-3-[(2,3,6-trifluoro-4-methylphenyl)methoxy]- (9CI) (CA INDEX NAME)




RN 252003-60-4 HCAPLUS


L4 ANSWER 16 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 252003-63-7 HCAPLUS
 CN 4-Isothiazolecarboxamide, 3-[(4-bromo-2,6-trifluorophenyl)methoxy]-5-[[[4-(1-pyrrolidinyl)butyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 252003-64-8 HCAPLUS
 CN 4-Isothiazolecarboxamide, 5-[[[4-(bis(2-hydroxyethyl)amino)butyl]amino]carbonyl]amino]-3-[(2,6-difluoro-4-methylphenyl)methoxy]- (9CI) (CA INDEX NAME)




RN 252003-65-9 HCAPLUS
 CN 4-Isothiazolecarboxamide, 3-[(4-bromo-2,6-difluorophenyl)methoxy]-5-[[[4-(1-pyrrolidinyl)butyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 252003-66-0 HCAPLUS

L4 ANSWER 16 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

CN 4-Isothiazolecarboxamide, 5-[[[3-hydroxy-5-[(1-methylethyl)amino]pentyl]amino]carbonyl]amino]-3-[(2,3,6-trifluoro-4-methylphenyl)methoxy]- (9CI) (CA INDEX NAME)



RN 252003-61-5 HCAPLUS
 CN 4-Isothiazolecarboxamide, 5-[[[4-[4-(2-hydroxyethyl)-1-piperazinyl]butyl]amino]carbonyl]amino]-3-[(2,3,6-trifluoro-4-methylphenyl)methoxy]- (9CI) (CA INDEX NAME)




RN 252003-62-6 HCAPLUS
 CN 4-Isothiazolecarboxamide, 3-[(2,6-difluoro-4-methylphenyl)methoxy]-5-[[[2-(1-methyl-2-pyrrolidinyl)ethyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)

L4 ANSWER 16 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CN 4-Isothiazolecarboxamide, 3-[(4-bromo-2,6-difluorophenyl)methoxy]-5-[[[4-(1-pyrrolidinyl)butyl]amino]carbonyl]amino]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 252003-65-9
 CMF C20 H24 Br F2 N5 O3 S




CM 2

CRN 75-75-2
 CMF C H4 O3 S




RN 252003-67-1 HCAPLUS
 CN 4-Isothiazolecarboxamide, 5-[[[3-(4-methyl-1-piperazinyl)propyl]amino]carbonyl]amino]-3-[(2,3,6-trifluoro-4-methylphenyl)methoxy]- (9CI) (CA INDEX NAME)

L4 ANSWER 16 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 252003-68-2 HCAPLUS
 CN 4-Isothiazolecarboxamide, 3-[(4-chloro-2,6-difluorophenyl)methoxy]-5-[[[4-ethyl(2-hydroxyethyl)amino]butyl]amino]carbonylamino]- (9CI) (CA INDEX NAME)




RN 252003-69-3 HCAPLUS
 CN 4-Isothiazolecarboxamide, 3-[(2,5-difluoro-4-methylphenyl)methoxy]-5-[[[4-[4-(2-hydroxyethyl)-1-piperazinyl]butyl]amino]carbonylamino]- (9CI) (CA INDEX NAME)


L4 ANSWER 16 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 252003-72-8 HCAPLUS
 CN 4-Isothiazolecarboxamide, 3-[(4-chloro-2,6-difluorophenyl)methoxy]-5-[[[4-(1-pyrrolidinyl)butyl]amino]carbonylamino]- (9CI) (CA INDEX NAME)




RN 252003-73-9 HCAPLUS
 CN 4-Isothiazolecarboxamide, 3-[(4-chloro-2,6-difluorophenyl)methoxy]-5-[[[4-(4-methyl-1-piperazinyl)propyl]amino]carbonylamino]- (9CI) (CA INDEX NAME)




RN 252003-74-0 HCAPLUS

L4 ANSWER 16 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 252003-70-6 HCAPLUS
 CN 4-Isothiazolecarboxamide, 3-[(2-fluoro-4-methylphenyl)methoxy]-5-[[[5-[(1-methylethyl)amino]pentyl]amino]carbonylamino]- (9CI) (CA INDEX NAME)




RN 252003-71-7 HCAPLUS
 CN 4-Isothiazolecarboxamide, 3-[(4-bromo-2,6-difluorophenyl)methoxy]-5-[[[4-(1-pyrrolidinyl)butyl]amino]carbonylamino]-, monohydrochloride (9CI) (CA INDEX NAME)


L4 ANSWER 16 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CN 4-Isothiazolecarboxamide, 3-[(4-chloro-2,6-difluorophenyl)methoxy]-5-[[[2-(1-methyl-2-pyrrolidinyl)ethyl]amino]carbonylamino]- (9CI) (CA INDEX NAME)



RN 252003-75-1 HCAPLUS
 CN 4-Isothiazolecarboxamide, 3-[(2,5-difluoro-4-methylphenyl)methoxy]-5-[[[4-(3,4-dihydroxy-1-pyrrolidinyl)butyl]amino]carbonylamino]- (9CI) (CA INDEX NAME)




RN 252003-76-2 HCAPLUS
 CN 4-Isothiazolecarboxamide, 3-[(4-chloro-2,6-difluorophenyl)methoxy]-5-[[[4-(3,4-dihydroxy-1-pyrrolidinyl)butyl]amino]carbonylamino]- (9CI) (CA INDEX NAME)




RN 252003-77-3 HCAPLUS
 CN 4-Isothiazolecarboxamide, 3-[(2,5-difluoro-4-methylphenyl)methoxy]-5-[[[4-(2-(hydroxymethyl)-1-pyrrolidinyl)butyl]amino]carbonylamino]- (9CI) (CA INDEX NAME)


L4 ANSWER 16 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 252003-78-4 HCAPLUS
 CN 4-Isothiazolecarboxamide, 3-[(4-chloro-2,6-difluorophenyl)methoxy]-5-[[[4-(2-(hydroxymethyl)-1-pyrrolidiny)butyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 252003-79-5 HCAPLUS
 CN 4-Isothiazolecarboxamide, 3-[(2,5-difluoro-4-methylphenyl)methoxy]-5-[[[4-(3-hydroxy-1-pyrrolidiny)butyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 252003-80-8 HCAPLUS
 CN 4-Isothiazolecarboxamide, 3-[(2,6-difluoro-4-methylphenyl)methoxy]-5-[[[4-(hydroxy-5-(1-piperidiny)pentyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)

L4 ANSWER 16 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)


PAGE 2-A



RN 252003-82-0 HCAPLUS
 CN 4-Isothiazolecarboxamide, 3-[(4-chloro-2,6-difluorophenyl)methoxy]-5-[[[4-(2-(hydroxymethyl)-1-piperidiny)butyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 252003-83-1 HCAPLUS
 CN 4-Isothiazolecarboxamide, 3-[(2,5-difluoro-4-methylphenyl)methoxy]-5-[[[4-(ethyl 2-hydroxyethyl)amino]butyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 252003-84-2 HCAPLUS
 CN 4-Isothiazolecarboxamide, 3-[(4-chloro-2,6-difluorophenyl)methoxy]-5-[[[5-(hydroxy-6-(1-piperidiny)hexyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)

L4 ANSWER 16 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 252003-81-9 HCAPLUS
 CN 4-Isothiazolecarboxamide, 3-[(2,5-difluoro-4-methylphenyl)methoxy]-5-[[[3-(hydroxy-5-(1-piperidiny)pentyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)


PAGE 1-A



L4 ANSWER 16 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 252003-85-3 HCAPLUS
 CN 4-Isothiazolecarboxamide, 3-[(4-bromo-2,3,6-trifluorophenyl)methoxy]-5-[[[3-(4-methyl-1-piperaziny)propyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 252003-86-4 HCAPLUS
 CN 4-Isothiazolecarboxamide, 3-[(2,6-difluoro-4-methylphenyl)methoxy]-5-[[[3-(4-methyl-1-piperaziny)propyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)

L4 ANSWER 16 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 252003-87-5 HCAPLUS
 CN 4-isothiazolecarboxamide, 5-[[[3-hydroxy-5-(1-pyrrolidinyl)pentyl]amino]carbonyl]amino-3-[(2,3,6-trifluoro-4-methylphenyl)methoxy]- (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 1-B

Me
 RN 252003-88-6 HCAPLUS
 CN 4-isothiazolecarboxamide, 3-[(4-chloro-2,6-difluorophenyl)methoxy]-5-[[[3-(5-methyl-2,5-diazabicyclo[2.2.1]hept-2-yl)propyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)


L4 ANSWER 16 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 252003-92-2 HCAPLUS
 CN 4-isothiazolecarboxamide, 3-[(4-chloro-2,3,6-trifluorophenyl)methoxy]-5-[[[4-(2-(hydroxymethyl)-1-pyrrolidinyl)butyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 252003-93-3 HCAPLUS
 CN 4-isothiazolecarboxamide, 5-[[[3-(dimethylamino)propyl]amino]carbonyl]amino-3-[(2,3,6-trifluoro-4-methylphenyl)methoxy]- (9CI) (CA INDEX NAME)




RN 252003-94-4 HCAPLUS
 CN 4-isothiazolecarboxamide, 5-[[[3-(1-methylethyl)amino]propyl]amino]carbonyl]amino-3-[(2,3,6-trifluoro-4-methylphenyl)methoxy]- (9CI) (CA INDEX NAME)




L4 ANSWER 16 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 252003-89-7 HCAPLUS
 CN 4-isothiazolecarboxamide, 3-[(4-chloro-2,3,6-trifluorophenyl)methoxy]-5-[[[3-(5-methyl-2,5-diazabicyclo[2.2.1]hept-2-yl)propyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 252003-90-0 HCAPLUS
 CN 4-isothiazolecarboxamide, 3-[(4-chloro-2,3,6-trifluorophenyl)methoxy]-5-[[[2-(1-methyl-2-pyrrolidinyl)ethyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 252003-91-1 HCAPLUS
 CN 4-isothiazolecarboxamide, 3-[(4-chloro-2,3,6-trifluorophenyl)methoxy]-5-[[[4-(1-pyrrolidinyl)butyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)

L4 ANSWER 16 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 252003-95-5 HCAPLUS
 CN 4-isothiazolecarboxamide, 5-[[[4-(4-methyl-1-piperazinyl)butyl]amino]carbonyl]amino-3-[(2,3,6-trifluoro-4-methylphenyl)methoxy]- (9CI) (CA INDEX NAME)




RN 252003-96-6 HCAPLUS
 CN 4-isothiazolecarboxamide, 5-[[[3-(1-pyrrolidinyl)propyl]amino]carbonyl]amino-3-[(2,3,6-trifluoro-4-methylphenyl)methoxy]- (9CI) (CA INDEX NAME)




RN 252003-97-7 HCAPLUS
 CN 4-isothiazolecarboxamide, 5-[[[4-(hydroxy-5-(1-piperidinyl)pentyl)amino]carbonyl]amino]-3-[(2,3,6-trifluoro-4-methylphenyl)methoxy]- (9CI) (CA INDEX NAME)


L4 ANSWER 16 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 252003-98-8 HCAPLUS
 CN 4-Isouthiazolecarboxamide, 3-[(4-chloro-2,6-difluorophenyl)methoxy]-5-[[[4-(1H-imidazol-1-yl)butyl]amino]carbonyl]amino- (9CI) (CA INDEX NAME)




RN 252003-99-9 HCAPLUS
 CN 4-Isouthiazolecarboxamide, 5-[[[4-(ethyl(2-hydroxyethyl)amino)butyl]amino]carbonyl]amino]-3-[(2,3,6-trifluoro-4-methylphenyl)methoxy]- (9CI) (CA INDEX NAME)




L4 ANSWER 16 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 252004-03-8 HCAPLUS
 CN 4-Isouthiazolecarboxamide, 3-[(2,6-difluoro-4-methylphenyl)methoxy]-5-[[[4-(dimethylamino)butyl]amino]carbonyl]amino- (9CI) (CA INDEX NAME)




RN 252004-04-9 HCAPLUS
 CN 4-Isouthiazolecarboxamide, 3-[(2,6-difluoro-4-methylphenyl)methoxy]-5-[[[3-(dimethylamino)propyl]amino]carbonyl]amino- (9CI) (CA INDEX NAME)




RN 252004-05-0 HCAPLUS
 CN 4-Isouthiazolecarboxamide, 3-[(4-chloro-2,3,6-trifluorophenyl)methoxy]-5-[[[4-(1H-imidazol-1-yl)butyl]amino]carbonyl]amino- (9CI) (CA INDEX NAME)

L4 ANSWER 16 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 252004-00-5 HCAPLUS
 CN 4-Isouthiazolecarboxamide, 3-[(4-chloro-2,3,6-trifluorophenyl)methoxy]-5-[[[4-(2-hydroxyethyl)-1-piperidyl]butyl]amino]carbonyl]amino- (9CI) (CA INDEX NAME)



RN 252004-01-6 HCAPLUS
 CN 4-Isouthiazolecarboxamide, 3-[(4-chloro-2,3,6-trifluorophenyl)methoxy]-5-[[[3-hydroxy-5-(1-pyrrolidiny)pentyl]amino]carbonyl]amino- (9CI) (CA INDEX NAME)




PAGE 1-A

PAGE 1-B


L4 ANSWER 16 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 252004-02-7 HCAPLUS
 CN 4-Isouthiazolecarboxamide, 3-[(4-bromo-2,6-difluorophenyl)methoxy]-5-[[[3-(4-methyl-1-piperazinyl)propyl]amino]carbonyl]amino- (9CI) (CA INDEX NAME)


L4 ANSWER 16 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 252004-07-2 HCAPLUS
 CN 4-Isouthiazolecarboxamide, 3-[(4-chloro-2,3,6-trifluorophenyl)methoxy]-5-[[[3-(4-methyl-1-piperazinyl)propyl]amino]carbonyl]amino- (9CI) (CA INDEX NAME)



RN 252004-08-3 HCAPLUS
 CN 4-Isouthiazolecarboxamide, 5-[[[3-(methylamino)propyl]amino]carbonyl]amino]-3-[(2,3,6-trifluoro-4-methylphenyl)methoxy]- (9CI) (CA INDEX NAME)




RN 252004-09-4 HCAPLUS
 CN 4-Isouthiazolecarboxamide, 5-[[[3-(aminopropyl)methylamino]carbonyl]amino]-3-[(2,3,6-trifluoro-4-methylphenyl)methoxy]- (9CI) (CA INDEX NAME)




RN 252004-10-7 HCAPLUS


L4 ANSWER 16 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN 4-Isothiazolecarboxamide, 5-[[[(4-(diethylamino)butyl)amino]carbonyl]amino]-3-[(2,3,6-trifluoro-4-methylphenyl)methoxy]- (9CI) (CA INDEX NAME)



RN 252004-11-8 HCAPLUS
CN 4-Isouthiazolecarboxamide, 3-[(2,6-difluoro-4-methylphenyl)methoxy]-5-[[[(1-pyrrolidinyl)propyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 252004-12-9 HCAPLUS
CN 4-Isouthiazolecarboxamide, 3-[(3-chloro-2,6-difluoro-4-methylphenyl)methoxy]-5-[[[(4-(dimethylamino)butyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 17 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RN 65553-13-1 HCAPLUS
CN 4-Isouthiazolecarboxamide, 5-[(2,2-dimethyl-1-oxopropyl)amino]-3-(methylthio)- (9CI) (CA INDEX NAME)




RN 65553-16-4 HCAPLUS
CN 4-Isouthiazolecarboxamide, 3-(ethylthio)-5-[[[(methylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 65553-18-6 HCAPLUS
CN 4-Isouthiazolecarboxamide, 5-[[[(dimethylamino)carbonyl]amino]-3-(ethylthio)- (9CI) (CA INDEX NAME)



RN 65553-20-0 HCAPLUS
CN 4-Isouthiazolecarboxamide, 5-[[[(dimethylamino)carbonyl]amino]-3-(ethylsulfonyl)- (9CI) (CA INDEX NAME)



RN 65553-21-1 HCAPLUS


L4 ANSWER 17 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1978:121158 HCAPLUS
DOCUMENT NUMBER: 88:121158
TITLE: 3-Alkylthio-, 3-alkylsulfinyl-, and 3-alkylsulfonylisothiazole derivatives as herbicides
INVENTOR(S): Gibbons, Loren Kenneth
PATENT ASSIGNEE(S): FMC Corp., USA
SOURCE: U.S., 9 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4057416	A	19771108	US 1976-697458	19760618


PRIORITY APPLN. INFO.:
IT 65553-05-1P 65553-10-8P 65553-13-1P
65553-16-4P 65553-18-6P 65553-20-0P
65553-21-1P 65553-22-2P 65553-23-3P
65553-24-4P 65553-26-6P 65553-28-8P
65553-31-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and herbicidal activity of)


RN 65553-05-1 HCAPLUS
CN 4-Isouthiazolecarboxamide, 5-[[[(methylamino)carbonyl]amino]-3-(methylsulfonyl)- (9CI) (CA INDEX NAME)




RN 65553-10-8 HCAPLUS
CN 4-Isouthiazolecarboxamide, 5-[[[(methylamino)carbonyl]amino]-3-(methylsulfonyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 17 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN 4-Isouthiazolecarboxamide, 3-(ethylsulfonyl)-5-[[[(methylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 65553-22-2 HCAPLUS
CN 4-Isouthiazolecarboxamide, 3-(ethylsulfinyl)-5-[[[(methylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 65553-23-3 HCAPLUS
CN 4-Isouthiazolecarboxamide, 5-[[[(methylamino)carbonyl]amino]-3-(propylthio)- (9CI) (CA INDEX NAME)




RN 65553-24-4 HCAPLUS
CN 4-Isouthiazolecarboxamide, 5-[[[(dimethylamino)carbonyl]amino]-3-(propylthio)- (9CI) (CA INDEX NAME)




RN 65553-26-6 HCAPLUS


L4 ANSWER 17 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CN 4-Isothiazolecarboxamide, 5-[[[(methylamino)carbonyl]amino]-3-(propylsulfonyl)]- (9CI) (CA INDEX NAME)



RN 65553-28-8 HCAPLUS
 CN 4-Isouthiazolecarboxamide, 5-[[[(dimethylamino)carbonyl]amino]-3-(propylsulfonyl)]- (9CI) (CA INDEX NAME)



RN 65553-31-3 HCAPLUS
 CN 4-Isouthiazolecarboxamide, 5-[[[(methylamino)carbonyl]amino]-3-[(1-methylethyl)thio]]- (9CI) (CA INDEX NAME)




IT 65553-09-5P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation, herbicidal activity, and oxidation of)
 RN 65553-09-5 HCAPLUS
 CN 4-Isouthiazolecarboxamide, 5-[[[(methylamino)carbonyl]amino]-3-(methylthio)]- (9CI) (CA INDEX NAME)


L4 ANSWER 18 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1978:50846 HCAPLUS
 DOCUMENT NUMBER: 88:50846
 TITLE: 3-Alkoxyisothiazole derivatives as herbicides
 INVENTOR(S): Gibbons, Loren Kenneth
 PATENT ASSIGNEE(S): FMC Corp., USA
 SOURCE: U.S., 7 pp.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4059433	A	19771122	US 1976-697457	19760618
PRIORITY APPLN. INFO.:			US 1976-697457	A 19760618

IT 65342-77-0P 65342-79-2P 65374-60-9P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation and herbicidal activity of)
 RN 65342-77-0 HCAPLUS
 CN 4-Isouthiazolecarboxamide, 5-[[[(dimethylamino)carbonyl]amino]-3-ethoxy]- (9CI) (CA INDEX NAME)




RN 65342-79-2 HCAPLUS
 CN 4-Isouthiazolecarboxamide, 5-[[[(methylamino)carbonyl]amino]-3-propoxy]- (9CI) (CA INDEX NAME)




RN 65374-60-9 HCAPLUS
 CN 4-Isouthiazolecarboxamide, 5-[[[(2-methyl-1-oxopropyl)amino]-3-propoxy]- (9CI) (CA INDEX NAME)


L4 ANSWER 17 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




L4 ANSWER 18 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



L4 ANSWER 19 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1965:9101 HCAPLUS
DOCUMENT NUMBER: 62:9101
ORIGINAL REFERENCE NO.: 62:1654b-h,1655a-f
TITLE: Isothiazoles. VI. Synthesis of 5-amino-3-hydroxy(-alkoxy-, -amino-)isothiazoles and of derivatives of pyrimidine-4-thione
AUTHOR(S): Goerdeler, Joachim; Keuser, Ulrich
CORPORATE SOURCE: Univ. Bonn, Germany
SOURCE: Chemische Berichte (1964), 97(11), 3106-17
CODEN: CHBEAM; ISSN: 0009-2940
DOCUMENT TYPE: Journal
LANGUAGE: German
OTHER SOURCE(S): CASREACT 62:9101
IT 1141-16-8, 4-Isothiazolecarboxamide, 5-anilino-3-hydroxy-
1160-12-9, 4-Isothiazolecarboxamide, 3-hydroxy-5-(N-phenylacetamido)-, acetate (ester)
(preparation of)
RN 1141-16-8 HCAPLUS
CN 4-Isothiazolecarboxamide, 2,3-dihydro-3-oxo-5-(phenylamino)- (9CI) (CA INDEX NAME)



RN 1160-12-9 HCAPLUS
CN 4-Isothiazolecarboxamide, 3-hydroxy-5-(N-phenylacetamido)-, acetate (ester) (8CI) (CA INDEX NAME)



=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

69.31

230.85

STN INTERNATIONAL LOGOFF AT 14:59:48 ON 12 SEP 2005